

**CURRICULUM VITAE  
FOR  
CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE**

**MARCH 22, 2026**

**PERSONAL INFORMATION**

Name:	Barnett, Brian S
Credentials:	MD
Institution & Institute	Cleveland Clinic / Neurological Institute
Department	Psychiatry and Psychology
Office Address & Mail Code	Lutheran Hospital, 1730 W. 25 <sup>th</sup> Street, Cleveland, OH
Home Address	7409 Tattersall Drive, Chesterland, OH 44026
Office Phone	216-536-7857
Office Email	barnetb3@ccf.org

**EDUCATION & TRAINING**

**Education**

School & City, State / Country	Case Western Reserve University, Cleveland, OH
Degree	Master of Business Administration
Start-End Dates	09/2025-Present
School & City, State / Country	University of Pennsylvania, Philadelphia, PA
Degree	BA, Biology and Anthropology
Start-End Dates	06/2004-05/2008
School & City, State / Country	Vanderbilt University, Nashville, TN
Degree	MD with graduate certificate in global health
Start-End Dates	07/2008-05/2013
School & City, State / Country	Fulbright-Fogarty Public Health Fellowship, Lilongwe, Malawi
Degree	Certificate
Start-End Dates	08/2011-06/2012

**Post-Graduate Training**

Institution & City, State / Country	Massachusetts General/McLean Hospital Psychiatry Residency
Position	Intern and Resident
Start-End Dates	06/2013-06/2017
Institution & City, State / Country	Massachusetts General/McLean Hospital Psychiatry Residency
Position	Chief Resident, Addictions
Start-End Dates	07/2016-06/2017
Institution & City, State / Country	Partners Healthcare Addiction Psychiatry Fellowship (Massachusetts General Hospital, Brigham and Women's Hospital, & McLean Hospital)
Position	Clinical Fellow
Start-End Dates	07/2017-06/2018
Institution & City, State / Country	University Hospitals/Case Western Reserve University Forensic Psychiatry Fellowship
Position	Clinical Fellow
Start-End Dates	07/2018-06/2019

**ACADEMIC APPOINTMENTS (University and School)**

Rank, Department Assistant Professor of Psychiatry  
Institution & City, State / Country Cleveland Clinic Lerner College of Medicine of Case Western Reserve  
University School of Medicine, Cleveland, OH  
Start-End Dates 06/2020-Present

**PROFESSIONAL APPOINTMENTS**

Position Clinical Director, Spravato (Esketamine) Service  
Institution & Institute Cleveland Clinic Lutheran Hospital  
Department Psychiatry and Psychology  
City, State / Country Cleveland, OH  
Start-End Dates 08/2023-Present

Position Associate Program Director  
Institution & Institute Case Western Reserve University/University Hospitals Cleveland Medical  
Center Addiction Psychiatry Fellowship  
Department Psychiatry  
City, State / Country Cleveland, OH  
Start-End Dates 07/2023-Present

Position Clinical Director, Psychiatric Treatment Resistance Program  
Institution & Institute Cleveland Clinic, Neurological Institute  
Department Psychiatry and Psychology  
City, State / Country Cleveland, OH  
Start-End Dates 06/2021-Present

Position Staff Psychiatrist  
Institution & Institute Cleveland Clinic, Neurological Institute  
Hospital Privileges: Hillcrest Hospital, Lutheran Hospital, Main Campus, Marymount Hospital  
& South Pointe Hospital  
Department Psychiatry and Psychology  
City, State / Country Cleveland, OH  
Start-End Dates 08/2019-Present

**PAST EMPLOYMENT (excluding training)**

Institution & City, State / Country Newton Wellesley Hospital  
Position Moonlighter  
Start-End Dates 2016-2018

Institution & City, State / Country Bayridge Hospital, Lynn, MA  
Position Moonlighter  
Start-End Dates 2015-2018

Institution & City, State / Country Mount Auburn Hospital  
Position Moonlighter  
Start-End Dates 2015-2018

Institution & City, State / Country Bridgewater State Hospital, Bridgewater, MA  
Position Moonlighter  
Start-End Dates 2015-2016

Institution & City, State / Country McLean Hospital  
Position Moonlighter  
Start-End Dates 2015-2018

**ADDITIONAL CAREER DEVELOPMENT**

**Leadership Development**

School / Institution Partners Healthcare Center of Expertise in Health Policy and Management  
Title /Certificate Health Policy Course Certificate  
Start-End Dates 02/2017-03/2017

**Educator Development**

School / Institution Harvard Catalyst  
Title /Certificate Applied Biostatistics  
Start-End Dates 09/2016-06/2017

**Clinical Development**

School / Institution Harvard Business School  
Title /Certificate Value Based Healthcare Course Certificate  
Start-End Dates 01/2018-01/2018

**Research Development**

School/Institution: Martinos Center, Boston, MA  
Title /Certificate Functional MRI Workshop: A Five-Day Intensive Introduction  
Start-End Dates October 21-25, 2023

**CERTIFICATION & LICENSURE**

**Certification**

Name of Board American Board of Psychiatry and Neurology Certificate, General Psychiatry  
Certificate Number (if applicable) 72366  
Date Issued & Expires 2017-2027

Name of Board American Board of Psychiatry and Neurology Certificate, Addiction Psychiatry  
Certificate Number (if applicable) 2540  
Date Issued & Expires 2018-2028

Name of Board American Board of Psychiatry and Neurology Certificate, Forensic Psychiatry  
Certificate Number (if applicable) 2540  
Date Issued & Expires 2019-2029

**Licensure**

Name of State Medical Board Massachusetts Board of Registration in Medicine  
License Number 264974  
Date Issued & Expires 2015-2019

Name of State Medical Board State Medical Board of Ohio  
License Number 129607  
Date Issued & Expires 2016-Present

Name of State Medical Board Montana Board of Medical Examiners  
License Number 68781  
Date Issued & Expires 2018-2020

Name of State Medical Board Kentucky Board of Medical Licensure  
License Number 52543  
Date Issued & Expires 2019-Present

### **MEMBERSHIP IN PROFESSIONAL SOCIETIES**

Name of Society                      Massachusetts Psychiatric Society  
Role / Title                              Member  
Start-End Dates                        2013-2019

Name of Society                      American Psychiatric Association  
Role / Title                              Member  
Start-End Dates                        2013-Present

Name of Society                      American Academy of Psychiatry and the Law  
Role / Title                              Member  
Start-End Dates                        2014-Present

Name of Society                      American Academy of Addiction Psychiatry  
Role / Title                              Member  
Start-End Dates                        2016-Present

Name of Society                      Ohio Psychiatric Physicians Association  
Role / Title                              Member  
Start-End Dates                        2018-Present

Name of Society                      American Society of Addiction Medicine  
Role / Title                              Member  
Start-End Dates                        2019-Present

Name of Society                      Society of Biological Psychiatry  
Role / Title                              Member  
Start-End Dates                        2021-Present

Name of Society                      Academy of Consultation-Liaison Psychiatry  
Role / Title                              Member  
Start-End Dates                        2021-Present

### **PROFESSIONAL SERVICES**

#### **Ad Hoc Grant Reviewer**

Organization: National Institutes of Health  
Committee: Center for Scientific Review, Special Emphasis Panel Meeting 2025/05 ZRG1 BP-M (70) R  
Role: Mail reviewer  
Date: 11/2024

#### **Ad Hoc Manuscript Reviewer**

Journal 1                                Psychosomatics  
Start-End Dates                        2016-Present

Journal 2                                Journal of the American Academy of Psychiatry and the Law  
Start-End Dates                        2019-Present

Journal 3                                Substance Abuse  
Start-End Dates                        2019-Present

Journal 4                                Injury  
Start-End Dates                        2020-Present

Journal 5                                Frontiers in Psychiatry

Start-End Dates	2021-Present
Journal 6 Start-End Dates	Journal of Psychoactive Drugs 2021-Present
Journal 7 Start-End Dates	Cleveland Clinic Journal of Medicine 2021-Present
Journal 8 Start-End Dates	Frontiers in Psychology 2022-Present
Journal 9 Start-End Dates	Frontiers in Pharmacology 2022-Present
Journal 10 Start-End Dates	International Journal of Drug Policy 2022-Present
Journal 11 Start-End Dates	Journal of Psychopharmacology 2022-Present
Journal 12 Start-End Dates	Psychiatry Research Case Reports 2022-Present
Journal 13 Start-End Dates	Frontiers in Neuroscience 2022-Present
Journal 14 Start-End Dates	Plos One 2022-Present
Journal 15 Start-End Dates	Psychedelic Medicine 2023-Present
Journal 16 Start-End Dates	Journal of Psychedelic Studies 2023-Present
Journal 17 Start-End Dates	Alcohol and Alcoholism 2023-Present
Journal 18 Start-End Dates	Pharmacological Research 2023-Present
Journal 19 Start-End Dates	Journal of Neuroimaging 2023-Present
Journal 20 Start-End Dates	AMA Journal of Ethics 2023-Present
Journal 21 Start-End Dates	BMJ Open 2024-Present
Journal 22 Start-End Dates	Dermatitis 2024-Present
Journal 23 Start-End Dates	Psychiatry Research 2024-Present

Journal 24 Start-End Dates	Drugs: Education, Prevention and Policy 2024-Present
Journal 25 Start-End Dates	Permanente Journal 2024-Present
Journal 26 Start-End Dates	JAMA Network Open 2024-Present
Journal 27 Start-End Dates	Heliyon 2024-Present
Journal 28 Start-End Dates	Transcultural Psychiatry 2024-Present
Journal 29 Start-End Dates	Primary Care Companion for CNS Disorders 2024-Present
Journal 30 Start-End Dates	British Journal of Clinical Pharmacology 2024-Present
Journal 31 Start-End Dates	Drug Science, Policy and Law 2024-Present
Journal 32 Start-End Dates	JAMA Health Forum 2024-Present
Journal 33 Start-End Dates	Journal of Clinical Psychiatry 2024-Present
Journal 34 Start-End Dates	Dialogues in Clinical Neuroscience 2024-Present
Journal 35 Start-End Dates	Journal of Medical Internet Research 2024-Present
Journal 36 Start-End Dates	Journal of Addiction Medicine 2024-Present
Journal 37 Start-End Dates	Cancer Investigation 2024-Present
Journal 38 Start-End Dates	International Journal of Mental Health Nursing 2024-Present
Journal 39 Start-End Dates	BMC Complementary Medicine and Therapies 2024-Present
Journal 40 Start-End Dates	New England Journal of Medicine 2025-Present
Journal 41 Start-End Dates	JAMA Psychiatry 2025-Present
Journal 42 Start-End Dates	Nordic Journal of Psychiatry 2025-Present

Journal 43 Start-End Dates	Preventive Medicine Reports 2025-Present
Journal 44 Start-End Dates	Journal of Correctional Health Care 2025-Present
Journal 45 Start-End Dates	Journal of Affective Disorders 2025-Present
Journal 46 Start-End Dates	Sociology Compass 2025-Present
Journal 46 Start-End Dates	Clinical Neuropharmacology 2025-Present
Journal 46 Start-End Dates	JAMA Internal Medicine 2025-Present
Journal 47 Start-End Dates	Pharmacoeconomics and Policy 2025-Present
Journal 48 Start-End Dates	Brain Disorders 2025-Present
Journal 49 Start-End Dates	Australian and New Zealand Journal of Psychiatry 2025-Present

**Editorial Board Member**

Journal 1 Start-End Dates	Psychedelic Medicine 2022-Present
Journal 2 Start-End Dates	Clinical Neuropharmacology 2025-Present

**Guest editor**

Journal 1 Topic Start-End Dates	Frontiers in Psychiatry Psychedelics as Treatments for Substance Use Disorders 2022-2023
---------------------------------------	--

**Advisory Groups**

Organization Title Start-End Dates	CB Therapeutics Advisory board member 01/2020 to present
Organization Title Start-End Dates	Livanova Advisory board member 04/2024 to 04/2024
Organization Title	Massachusetts General Hospital Chair, Data Safety and Monitoring Board for Clinical trial: Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)

Start-End Dates	07/2024- Present
Organization	Janssen Pharmaceuticals
Title	Advisory board member
Start-End Dates	10/2024 to 10/2024
Organization	Association for Prescription Psychedelics
Title	Scientific advisor
Start-End Dates	11/2024 to present
Organization	MindMed
Title	Advisory board member
Start-End Dates	12/2024 to present
Organization	Cuyahoga County Drug Court Advisory Board
Title	Advisor
Start-End Dates	1/2025 to present
Organization	Abbvie
Title	Scientific advisor
Start-End Dates	02/2025 to present

**Administrative positions**

Position	Director
Institution & Institute	Cleveland Clinic Psychiatry Treatment Resistance Program
Department	Psychiatry and Psychology
City, State / Country	Cleveland, OH
Start-End Dates	07/2021-Present

**COMMITTEE SERVICE**

**National**

Organization	American Academy of Addiction Psychiatry
Committee Name / Role	Controversial Issues/Member – Contributed expert review and discussion of emerging and contentious clinical, ethical, and policy issues in addiction psychiatry, helping inform educational programming and organizational positions.
Start-End Dates	11/2019-11/2022

**Cleveland Clinic**

Committee Name / Role	Pharmacy and Therapeutics /Member
Start-End Dates	12/2019-Present
Committee Name / Role	Lutheran Hospital Credentialing Committee /Member
Start-End Dates	7/2020-Present

**Educational Committees**

Organization	Massachusetts General/McLean Hospital Psychiatry Residency Program
Committee Name / Role	Admissions Committee/Member
Start-End Dates	07/2016-06/2017
Organization	Cleveland Clinic
Committee Name / Role	Residency Competency Committee/Member
Start-End Dates	08/2020-06/2024
Organization	Cleveland Clinic

Committee Name / Role  
Start-End Dates

Residency Curriculum Committee/Member  
05/2021-Present

### **HONORS & AWARDS**

Overall Research Fellowship, Vanderbilt University School of Medicine	05/2009
Fulbright-Fogarty Fellowship in Public Health, Fulbright Program/Fogarty International	08/2011
American Academy of Addiction Psychiatry Resident Travel Award	12/2016
Joyce and Richard Tedlow Award, Massachusetts General Hospital	06/2017
Adult Psychiatry Training Program Teacher of the Year Award, Cleveland Clinic	08/2021
Henry Nasrallah Psychopharmacology Lecture Award, Ohio Psychiatric Physicians Annual Meeting	04/2024
Rosalind Franklin Society Special Award in Science for contributions to <i>Psychedelic Medicine</i>	01/2025

### **TEACHING ACTIVITIES**

#### **Invited Lectures**

##### **National**

1. Psychedelics and addictions. Massachusetts General Hospital 1st Annual Conference on Psychedelics and Psychedelic Medicine, Boston, Massachusetts, conference attendees, 11/2021
2. Psychedelics and addictions. Massachusetts General Hospital 2nd Annual Conference on Psychedelics and Psychedelic Medicine, Boston, Massachusetts, conference attendees, 11/2022
3. Psychedelics - a reemerging treatment for behavioral health conditions. Risk Appraisal Forum, Cleveland, OH, Risk Appraisal Forum members (Life insurance underwriters), 10/06/2023
4. Psychedelics and addictions. Massachusetts General Hospital 3rd Annual Conference on Psychedelics and Psychedelic Medicine, Boston, Massachusetts, conference attendees, 11/2023
5. What role will psychedelics play in the future of behavioral health?, Association for Behavioral Health and Wellness (ABHW), virtual, ABHW members as well as executives from national health insurers, 09/17/2024
6. Psychedelics and addictions. Massachusetts General Hospital 4th Annual Conference on Psychedelics and Psychedelic Medicine, Boston, Massachusetts, conference attendees, 11/15/2024
7. Who's Going to Pay for All This? Challenges of Psychedelic Rollout in Hospital Psychiatry. Massachusetts General Hospital 4th Annual Conference on Psychedelics and Psychedelic Medicine, Boston, Massachusetts, conference attendees, 11/16/2024
8. Novel Therapies for Neuropsychiatry, TD Cowen annual "Cool Wheels" event, Boston, Massachusetts, institutional biotechnology investors, 01/09/2025
9. **Barnett BS**, Krystal J, and Thase M. Neuropsychiatry Panel, TD Cowen 45<sup>th</sup> Annual Health Care Conference, Boston, Massachusetts, conference attendees (healthcare investment community), 03/04/2025. Panel member.
10. **Barnett BS**, Falcone T, Altinay M, and Ferber S. Navigating Advanced Therapies for Treatment-Resistant Depression: ECT, Ketamine, MAOIs, and TMS, 05/17/2025, American Psychiatry Association Annual Meeting, conference attendees, podium presentation, 05/2025. Chair.
11. **Barnett BS**, Dalthorp R, Huber S, and Davis Q. The Future of Behavioral Health Treatments: What's on the Horizon? Becker's Behavioral Health Summit. 06/19/2025. Panel member.

##### **Regional**

1. Countering the Resurgence of Methamphetamine, Kentucky Psychiatric Medical Association, conference attendees, 03/2018
2. Reconsidering Psychedelics, National Institute on Drug Abuse, Lexington, Kentucky Chapter, members, platform presentation, 12/2018.
3. Psychopharmacological Options in the Treatment of Substance Use Disorders, Florida Psychiatric Society Annual Meeting, conference attendees, 09/2018
4. Psychedelics and Addiction, Michigan Psychedelic Society, society members, 06/2019
5. Is a psychedelic revolution coming to psychiatry? Ohio Psychiatric Physicians Association, Columbus, Ohio. 04/13/2024
6. Psychiatry Cases, 2024 Neurology Update - A Comprehensive Review for the Clinician, Cleveland Clinic CME review course, conference attendees, Washington, DC. 08/03/2024.
7. Rating Scales and the Signs and Symptoms of Catatonia, The Mid-Atlantic Psychiatric Updates Symposium: Catatonia, Old Dominion University's Eastern Virginia Medical Campus, Norfolk, Virginia. 03/25/2025.
8. Catatonia: Treatment Issues, The Mid-Atlantic Psychiatric Updates Symposium: Catatonia, Old Dominion University's Eastern Virginia Medical Campus, Norfolk, Virginia. 03/25/2025.

9. Ketamine in Psychiatry: Promise, Peril, and the Path Forward, Ohio Society of Addiction Medicine, Columbus, Ohio. 10/17/2025.

### **Local**

1. The Brain Disease Model of Addiction, Harvard Law School, law students, 02/2018
2. Incorporating research into a psychiatrist's career, Cleveland Psychiatric Society, members, platform presentation 05/09/2023
3. Treating depression: what's new and what's on the horizon? TD Cowen rounds. Cleveland Clinic. July 2023.
4. Psychedelics: A reemerging treatment for behavioral health conditions. Risk Appraisal Forum, Cleveland, Ohio, members, platform presentation, 10/05/2023.
5. Treatment Resistant Depression: Overview and Case Examples. Cleveland Clinic Primary Care +: Updates in Primary Care, Women's Health and Behavioral Medicine, Cleveland, Ohio, CME attendees, platform presentation, 11/11/2023.
6. Advanced Therapies in Mental Health Treatment: ECT, TMS, and Psychedelics. Cleveland Clinic Primary Care +: Updates in Primary Care, Women's Health and Behavioral Medicine, Cleveland, Ohio, CME attendees, platform presentation, 11/11/2023.
7. How does ketamine compare to electroconvulsive therapy for treatment resistant depression? Results from the ELEKT-D Trial, Cleveland Clinic Neurosciences Data on the Table seminar, Cleveland, Ohio, researchers, platform presentation, 12/11/2023.
8. Managing depression: An update for the internist, Cleveland Clinic, Department of Internal Medicine, department members, 01/18/2024.
9. Psychedelic Research at Cleveland Clinic, Cleveland Clinic, Neurological Institute, Trainee applicants attending Second Look, 02/19/2024
10. Behavioral Health Care and Research at Lutheran Hospital, Cleveland Clinic, Executive Leadership Committee, members, 03/15/2024
11. Psychiatry & Depression (New Drugs & Psychedelics) TD Cowen rounds @ Cleveland Clinic, TD Cowen Associates, platform presentation, 05/22/2024.
12. Is neurology the next frontier of the psychedelic renaissance? Cleveland Clinic Brain Study, study staff members, 07/15/2024
13. Attending Panel Discussion for Trainees, Cleveland Psychiatric Society, members, panel discussion, 07/16/2024

### **Grand Rounds**

#### **International**

1. Preparing for a paradigm shift: The potential of psychedelic-assisted therapy, American University Beirut Medical Center, Beirut, Lebanon, Department of Psychiatry, department members, 02/2023

#### **Regional**

1. Countering the Resurgence of Methamphetamine, University of Kentucky, department members, 12/2018
2. The complexities of caring for patients with catatonia. University of Louisville, Louisville, Kentucky. Grand Rounds. 02/22/2024
3. Is a psychedelic revolution coming to psychiatry?, Henry Ford Behavioral Health Grand Rounds, Detroit, Michigan, department members, 10/31/2024
4. Is a psychedelic revolution coming to psychiatry?, Pennsylvania State University Department of Psychiatry Grand Rounds, Hershey, Pennsylvania, 01/16/2025

#### **Local**

1. Can You Hear Me Now? How Language Can Both Hide and Reveal Identities, McLean Hospital, department members, 05/2018
2. Management of Sexual Behaviors on Inpatient Psychiatric Units in the #MeToo Era, University Hospitals, 03/2019
3. Evaluating Violence Risk and Duty to Protect: a Case Conference, Northcoast Behavioral Healthcare, department members, 04/2019
4. Ensuring Sexual Safety on Inpatient Psychiatric Units in the #MeToo Era, Cleveland Clinic, Department of Psychiatry and Psychology, department members, 09/2019

5. Federal and State Buprenorphine Law Review and Update—Making Compliance Easy. Cleveland Clinic, Buprenorphine prescribers continuing medical education course, CME attendees, 08/2020
6. Psychedelics in psychiatry: Ancient compounds, new science and evolving perspective. Cleveland Clinic, Department of Psychiatry and Psychology, department members, 12/2020.
7. Phencyclidine: Feel the city breakin' and everybody shakin' and we're stayin' alive, stayin' alive. Cleveland Clinic, Department of Psychiatry and Psychology, department members, 12/2021
8. Novel approaches to treatment resistant depression. Cleveland Clinic, Akron General Hospital Department of Psychiatry and Psychology, department members, 05/2023
9. Research update. Cleveland Clinic, Department of Psychiatry and Psychology, department members, 06/2023
10. Introduction to the Citywide Addiction Psychiatry Fellowship, Cleveland Clinic, Department of Psychiatry and Psychology, department members, 08/24/2023.
11. Preparing for a paradigm shift Therapeutic applications of psychedelics in psychiatry. Department of Psychiatry, Cleveland Veterans Affairs Hospital, Cleveland, Ohio, 12/7/2023
12. Research update. Cleveland Clinic, Department of Psychiatry and Psychology, department members, 03/07/2024
13. Is neurology the next frontier of the psychedelic renaissance? Cleveland Clinic, Department of Neurology, department members, 06/25/2024

## **Other Presentations**

### **International**

1. **Barnett B**, Tarpley M, Davidson M and Gbadero D. Delayed treatment in typhoid patients with perforated bowel in Nigeria, International Conference on Emerging Infectious Diseases, conference attendees, poster presentation, 07/2010.
2. **Barnett B**, Gokhale R, Krysiak R, Kanyemba C, Chikaonda T, Kalikokha M, Bokosi M, Mukuzunga C, Saidi F, Mpunga J, Phiri S, Hoffman I and Hosseinipour M. Comparison of tuberculosis diagnostic methods in an outpatient population in Lilongwe, Malawi. Keystone Symposia: Drug Resistance and Persistence in Tuberculosis, conference attendees, poster presentation, 05/2012.
3. **Barnett BS**, Ziegler K, Doblin R, Carlo AD. Is psychedelic use associated with cancer?: Interrogating a half-century-old claim using contemporary population-level data. Psychedemia, conference attendees, poster presentation, 08/2022.
4. Levin A, Aday J, **Barnett BS**, Liknaitzky P. American psychiatrists' changing views on psychedelics. Interdisciplinary Conference on Psychedelic Research, Haarlem, Netherlands, conference attendees, platform presentation, 06/07/2024.

### **National**

1. **Barnett BS**, Tarpley M, Davidson M and Gbadero D. Delayed treatment in typhoid patients with perforated bowel in Nigeria. American Society of Tropical Medicine and Hygiene, conference attendees, poster presentation, 11/2010.
2. **Barnett BS**, Tebaldi C, McHugh RK, Weiss R, and Bogunovic O. Clinical experience with injectable naltrexone treatment in sixteen patients with alcohol and opioid use disorders: retrospective case analysis. American Academy of Addiction Psychiatry, conference attendees, poster presentation, 12/2016.
3. **Barnett BS**, Nesbit A, Fisher K, and Sorrentino RM. Transgender Populations and the Law: Beyond the Bathroom, American Academy of Psychiatry and the Law, conference attendees, platform presentation, 10/2018.
4. Twark C, **Barnett BS**, Marcovitz D, Kim S, Bogunovic O, Boyajian C, Connery H, and Weiss R. that patients with opioid use disorder are not initiated on maintenance buprenorphine/naloxone prior to discharge from a detoxification unit, American Academy of Addiction Psychiatry, conference attendees, poster presentation, 12/2018.
5. West S, Vandercar A, **Barnett BS**, Noffsinger S. Covert Audio Recording of the Forensic Psychiatric Interview, American Psychiatric Association Annual Meeting, conference attendees, platform presentation, 05/2019.
6. Siu W, King F, Slowshower J, **Barnett BS**. Initiating Psychedelic Research and Critical Dialogue: Perspectives of Early Career Psychiatrists, American Psychiatric Association Annual Meeting, conference attendees, platform presentation, 05/2019.

7. Beaussant Y, **Barnett BS**, King F. Psychedelics: Treatment of the Future? An Interdisciplinary Discussion of the Risks, Benefits, and Current Evidence Supporting Psychedelic Therapy in Depression, Anxiety, and Substance Use Disorders, Consultation-Liaison Psychiatry Annual Meeting, conference attendees, platform presentation, 11/2019.
8. King F, Brown T, Cahn R, **Barnett BS**. Psychedelic treatments for substance use disorders: Preparing for a possible paradigm shift American Academy of Addiction Psychiatry Annual Meeting, conference attendees, platform presentation, 12/2019.
9. **Barnett BS** and Bodkin JA. The Powerful Influence of Medication Prior Authorization Requirements in American Psychiatry. American Academy of Addiction Psychiatry Annual Meeting, conference attendees, poster presentation, 12/2019.
10. **Barnett B**, Carlo A, Davenport S, Clement T, Harbin H. Psychiatry and Insurers: Parity, Patient Access and Prior Authorizations. American Psychiatry Association Annual Meeting, conference attendees, podium (virtual) presentation, 05/2020.
11. Accordino R, **Barnett B**, Benson N Carlo A, Davenport S. Ten Years after the Mental Health Parity and Addiction Equity Act (MHPAEA) - a Reawakening of Behavioral and Physical Health Parity in America. AcademyHealth Annual Research Meeting, platform presentation (accepted but cancelled due to COIVD-19), 06/2020.
12. Betterly H, Patel D, Karasin J, **Barnett BS**, Musselman M, and Mayer JLW. Improving Sexual Safety in Inpatient Psychiatric Facilities. American Psychiatry Association Annual Meeting, conference attendees, podium presentation, 05/2021.
13. **Barnett BS**, Noffsinger S, Hicks C, West S, and Saxton A. Maybe He's Born with It, Maybe It's Make Believe: Learning to Recognize the Many Faces of Malingering. American Psychiatry Association Annual Meeting, conference attendees, virtual presentation, 05/2021.
14. Benson N, Carlo AC, Song Z, **Barnett BS**, and Alter C. Mental Health Reimbursement and Its Implications for Patients, Providers, and Policy Makers. American Psychiatry Association Annual Meeting, conference attendees, virtual presentation, 05/2021.
15. Weleff J, Carlo AC, **Barnett BS**, and Knoll J. Aiming for Clarity at the Murky Intersection of Mental Illness, Psychiatry, and Firearm Ownership Rights. American Psychiatry Association Annual Meeting, conference attendees, virtual presentation, 05/2021.
16. Weleff J, **Barnett BS**, Carroll B, and Francis A. Catatonia: modern views of a classic illness. American Psychiatry Association Annual Meeting, conference attendees, podium presentation, 05/2022
17. Dore S, Weleff J, Anand A, Thompson N, and **Barnett BS**. Racial disparities in benzodiazepine prescription persist regardless of income A study analyzing benzodiazepine receipt in a primary care setting. American Psychiatry Association Annual Meeting, conference attendees, poster presentation, 05/2022
18. Weleff J, Bassir Nia A, **Barnett BS**. Psychedelics for Substance Use Disorders: Preparing for the Impending Paradigm Shift. American Society of Addiction Medicine, conference attendees, podium presentation, 04/2023.
19. **Barnett BS**, Beach S, Frichionne G, and Francis A. Catatonia: What should psychiatrists know and why? American Psychiatry Association Annual Meeting, conference attendees, podium presentation, 05/2023. Chair.
20. **Barnett BS**, Ferber S, Falcone T, and Altinay M. Exploring therapeutic applications of ketamine in psychiatry. American Psychiatry Association Annual Meeting, conference attendees, podium presentation, 05/2024. Chair.
21. **Barnett BS**, Hendricks P, O'Donnell K, and Garcia-Romeu A. Psychedelics in the treatment of substance use disorders. American Psychiatry Association Annual Meeting, conference attendees, podium presentation, 05/2024. Chair.

### Regional

1. **Barnett B**, Lapchenko M, Marcus Y and Noffsinger S. Starting and Building a Forensic Psychiatry Private Practice, The Midwest Chapter of the American Academy of Psychiatry and the Law, conference attendees, 03/2019

### Local

1. Lovell M and **Barnett B**. Alterations in the expression of zinc transporter protein-1 and zinc transporter protein-6 in the mild cognitive impairment brain, University of Kentucky, Department of Chemistry, Summer Research Symposium, symposium attendees, poster presentation, 07/2006.

2. Provance D, Karcher B, **Barnett B**, Chen D and Mercer J. Soluble fluorescent proteins: do they have inhibitory effects on myosins and important cellular pathways?, McLaughlin Research Institute Summer Research Symposium, symposium attendees, poster presentation, 08/2007.
3. Dixit R, **Barnett B**, Lazarus JE, Tokito M, Goldman YE, Holzbaur EL. Microtubule plus-end tracking by CLIP-170 requires EB1, University of Pennsylvania, Department of Biology, Symposium for Undergraduate Research, symposium attendees, poster presentation, 05/2008.
4. **Barnett BS**. The determination of hospice eligibility in patients with dementia, McLean Hospital, Geriatrics Unit, staff members, platform presentation, 01/2015.
5. **Barnett BS**. Efficacy and safety of deep transcranial magnetic stimulation for major depression, Psychiatry Residency Program, Massachusetts General and McLean Hospitals, trainees, platform presentation, 02/2015.
6. **Barnett B**, Owusu M, Ameresekere, M, and Shtasel, D. Synthetic cannabinoid usage in a transitional housing shelter: a survey to characterize usage patterns, Massachusetts General Hospital, Community Psychiatry Service, trainees, platform presentation, 04/2015.
7. **Barnett B**, Owusu M, Ameresekere, M, and Shtasel, D. Synthetic cannabinoid usage in a transitional housing shelter: a survey to characterize usage patterns, Massachusetts General Hospital Public and Community Psychiatry Symposium, symposium attendees, platform presentation, 04/2015.
8. **Barnett BS**. The use of mechanical restraints in psychiatric settings McLean Hospital, Psychotic Disorders Unit, staff, platform presentation, 06/2015.
9. **Barnett BS**. Erotic transference in the patient with borderline personality disorder McLean Hospital, Borderline Case Conference Series, staff, platform presentation, 09/2015.
10. **Barnett BS**. Beyond capacity- Forensics issues in consult psychiatry Massachusetts General Hospital, Consult Psychiatry Service, trainees, platform presentation, 11/2015.
11. **Barnett BS**. Psychedelics as treatment, Massachusetts General Hospital, Consult Psychiatry Service, trainees, platform presentation, 01/2016.
12. **Barnett BS**. Addiction, criminality and incarceration: What are we doing to break the cycle? Harvard Psychiatry Residents' Day, trainees, platform presentation, 11/2016.
13. **Barnett BS** and Sorrentino R. Autism spectrum disorder and problematic sexual behaviors Lurie Center for Autism, staff, platform presentation, 11/2016.
14. **Barnett BS**. Opioid dependence treatment with buprenorphine/naloxone, McLean Hospital Suboxone Training Course, for individuals seeking Suboxone license, platform presentation, 11/2017.
15. **Barnett BS**. Methamphetamine: A brief review Brigham and Women's Hospital, Addiction Consult Psychiatry Service, trainees, platform presentation, 12/2017.
16. Twark C, **Barnett BS**, Marcovitz D, Kim S, Bogunovic O, Boyajian C, Connery H, and Weiss R. Understanding the reasons that patients with opioid use disorder are not initiated on maintenance buprenorphine/naloxone prior to discharge from a detoxification unit. Harvard Psychiatry Research Day, conference attendees, poster presentation, 04/2018.
17. **Barnett BS**. Countering the resurgence of methamphetamine, Alcohol and Drug Abuse Treatment Program Seminar Series, McLean Hospital, for staff members, platform presentation, 05/2018.

### **Teaching Administration**

1. MGH/McLean Hospital Adult Psychiatry Residency, Boston, MA. "Great Concepts" Course Coordinator: 2014-2016.
2. MGH/McLean Hospital Adult Psychiatry Residency, Boston, MA. Residency Admissions Committee Member: 2016-2017.
3. MGH/McLean Hospital Adult Psychiatry Residency, Boston, MA. Addictions Chief Resident: 2017-2018.

### **Teaching Activities**

1. Harvard Medical School, Boston, MA. Clinical Fellow: 2013-2018. Provided teaching on the wards, individual supervision and group teaching to numerous medical students during their psychiatry clerkships. I also co-led a motivational interviewing training seminar each week for medical students and residents. Four hours per week.
2. Federal Judicial Center-Harvard Law School Workshop on Science-Informed Decision Making. Addictions Expert Consultant: 05/2018. Provided consultation to twenty federal judges working through hypothetical legal cases for defendants with mental health and substance issues.

3. Case Western Reserve University Forensic Psychiatry Fellowship, Cleveland, OH. Clinical teaching: 07/2018-06/2019. Taught approximately 20 medical students and residents on the wards. Also delivered formal lectures about violence and suicide risk assessments to approximately 25 medical students. Ten hours per week.

4. Cleveland Clinic, Cleveland, OH. Clinical Teaching: 08/2019-Present. Teach two Cleveland Clinic Lerner College of Medicine medical students and one resident on an inpatient psychiatry unit each month. I do one hour of structured supervision with another resident on evening shift each week. I also give an annual lecture to the Cleveland Clinic Lerner College of Medicine second year medical school class on addiction and its treatment. Additionally, I give several ad hoc lectures on various mental health and addiction topics to residents and students regularly. 20 hours a week. Each year I also formally lecture residents on psychedelics, MAOIs and first generation antipsychotics.

### **Teaching Lectures**

1. Addiction & Treatment. Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Annual lecture to second year medical students. 2019.
2. An Introduction to Psychedelics. Cleveland Clinic Psychiatry Residency Program. February 2020.
3. An Introduction to Quality Improvement. Cleveland Clinic Psychiatry Residency Program. Annual lecture to 3<sup>rd</sup> year residents. October 2020-present.
4. MAOIs: Psychiatry's Forgotten Weapons. Cleveland Clinic Psychiatry Residency Program. October 2020.
5. Addiction & Treatment. Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Annual lecture to second year medical students. November 2, 2020.
6. An Introduction to First Generation Antipsychotics. Cleveland Clinic Psychiatry Residency Program. Residents. January 2021.
7. Catatonia: The phantom hiding in plain sight. Cleveland Clinic Psychiatry Residency Program. Residents. July 14, 2021.
8. Addiction & Treatment. Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Annual lecture to second year medical students. November 1, 2021.
9. First Generation Antipsychotic Side Effect Management. Cleveland Clinic Psychiatry Residency Program. April 2021.
10. Introduction to Psychiatric Research. Cleveland Clinic Psychiatry Residency Program. Residents. December 05, 2021.
11. Measuring things in psychiatry. Cleveland Clinic Psychiatry Residency Program. Residents. January 04, 2022.
12. Tricyclic antidepressants: Forgotten friends. Cleveland Clinic Psychiatry Residency Program. Residents. May 05, 2022.
13. Catatonia: The phantom hiding in plain sight. Cleveland Clinic Psychiatry Residency Program. Residents. June 21, 2022.
14. Bipolar Disorder: An often misunderstood condition. Cleveland Clinic Psychiatry Residency Program. Residents. August 10, 2022.
15. Addiction & Treatment. Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Annual lecture to second year medical students. October 31, 2022.
16. Monoamine oxidase inhibitors (MAOIs): Psychiatry's forgotten weapons. Cleveland Clinic Psychiatry Residency Program. Residents. December 27, 2022.
17. Tricyclic antidepressants: Forgotten friends. Cleveland Clinic Psychiatry Residency Program. Residents. January 11, 2023.
18. Monoamine oxidase inhibitors (MAOIs): Psychiatry's forgotten weapons. Cleveland Clinic Psychiatry Residency Program. Residents. January 20, 2023.
19. What psychiatrists should know about statistics part 2. Cleveland Clinic Psychiatry Residency Program. May 11, 2023
20. Preparing for a Paradigm Shift: Investigating the potential and peril of psychedelic treatments in psychiatry. Cleveland Clinic Lerner College of Medicine medical students. June 2, 2023.
21. Addiction & Treatment. Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Annual lecture to second year medical students. June 5, 2023.

22. Psychedelics for Addictions. University Hospitals/Case Western Reserve University Addiction Psychiatry Fellowship. Addiction psychiatry fellows. July 19, 2023.
23. Catatonia: The phantom hiding in plain sight. Cleveland Clinic Psychiatry Residency Program. Residents. July 20, 2023.
24. Bipolar Disorder: An often misunderstood condition. Cleveland Clinic Psychiatry Residency Program. Residents. August 10, 2023.
25. Study design and execution. Cleveland Clinic Psychiatry Residency Program. Residents. October 5, 2023.
26. What psychiatrists should know about statistics part 1. Metrohealth Psychiatry Residency Program. Residents. October 25, 2023.
27. What psychiatrists should know about statistics part 2. Metrohealth Psychiatry Residency Program. Residents. November 1, 2023.
28. What psychiatrists should know about statistics part 1. Cleveland Clinic Psychiatry Residency Program. Residents. November 9, 2023.
29. Countering the resurgence of methamphetamine. Cleveland Clinic Psychiatry Residency Program. Residents. November 9, 2023.
30. What psychiatrists should know about statistics part 2. Cleveland Clinic Psychiatry Residency Program. Residents. November 16, 2023.
31. An Introduction to First Generation Antipsychotics. Cleveland Clinic Psychiatry Residency Program. Residents. December 7, 2023.
32. Introduction to Psychiatric Research. Cleveland Clinic Psychiatry Residency Program. Residents. December 21, 2023.
33. Academic Writing. University Hospitals/Case Western Reserve University Addiction Psychiatry Fellowship. January 3, 2024.
34. Measuring things in psychiatry. Cleveland Clinic Psychiatry Residency Program. Residents. January 25, 2024.
35. Bipolar Table Talk. Cleveland Clinic Psychiatry Residency Program. Residents. February 1, 2024.
36. Addiction boot camp: Marijuana and hallucinogens. Cleveland Clinic Psychiatry Residency Program. Residents. February 15, 2024.
37. The complexities of caring for patients with catatonia. Cleveland Clinic Child Psychiatry Fellowship Program. Fellows. March 21, 2024.
38. Academic Writing. Cleveland Clinic Psychiatry Residency Program. Residents. March 28, 2024.
39. Monoamine oxidase inhibitors (MAOIs): Psychiatry's forgotten weapons. Cleveland Clinic Psychiatry Residency Program. Residents. April 11, 2024.
40. Clinical Pearls. Cleveland Clinic Psychiatry Residency Program. Residents. May 2, 2024.
41. Tricyclic antidepressants: Forgotten friends. Cleveland Clinic Psychiatry Residency Program. Residents. May 16, 2024.
42. Substance use disorders & Treatment. Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Annual lecture to second year medical students. June 11, 2024.
43. Preparing for a Paradigm Shift: Investigating the potential and peril of psychedelic treatments in psychiatry. Cleveland Clinic Lerner College of Medicine medical students. June 14, 2024.

## **RESEARCH/GRANT SUPPORT (ONGOING)**

### **Federal**

Funding Type	Federal
Sponsor Agency and ID #	NIH/NIMH 5R01MH125214
Title of Project	Ketamine Treatment of Youth Suicide Attempters for Fast Reduction of Severe Suicide Risk and Facilitation of Long-term Collaborative Clinical Engagement: A Randomized Placebo Controlled Trial
PI of Grant	Tatiana Falcone, MD
If not PI, Your Role	Co-investigator, Director of Lutheran Hospital site
Percent Effort	3%
Total Direct Costs Awarded	\$1,196,484

Start-End Dates 10/2023- 08/2026

Funding Type Federal  
 Sponsor Agency and ID # PCORI 2023P001649  
 Title of Project Rapid Reversal of Acute Suicidal Depression across the Lifespan: A Pragmatic Comparative Effectiveness Trial of Electroconvulsive Therapy vs. Intravenous Ketamine Treatment (REaKT-SD)

PI of Grant Amit Anand, MD  
 If not PI, Your Role Co-PI for Cleveland Clinic site  
 Percent Effort 3%  
 Total Direct Costs Awarded \$3,377,645  
 Start-End Dates 07/2022- 10/2029

**Foundation**

Funding Type Foundation  
 Sponsor Agency and ID # MQ Foundation  
 Title of Project Neurobiological Markers of Hopelessness and Suicide Risk in Youth: A Multimodal MEG–MRI Study

PI of Grant Tataiana Falcone, MD  
 If not PI, Your Role Co-investigator, Director of Lutheran Hospital site  
 Percent Effort 5%  
 Total Direct Costs Awarded \$1,000,000  
 Start-End Dates 09/2025- 09/2030

**Industry**

Funding Type Industry  
 Sponsor Agency and ID # Abbott Medical Devices ABT-CIP-10494  
 Title of Project Treatment Resistant Depression Subcallosal Cingulate Network DBS (TRANSCEND)

PI of Grant Brian Kopell, MD & Mark George, MD  
 If not PI, Your Role Cleveland Clinic Site PI  
 Percent Effort N/A- Per participant contract  
 Start-End Dates 06/2025-06/2030

Funding Type Industry  
 Sponsor Agency and ID # MindMed MM120-300  
 Title of Project A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral MM120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder - Voyage

PI of Grant N/A- multisite industry sponsored trial  
 If not PI, Your Role Cleveland Clinic Site PI  
 Percent Effort N/A- Per participant contract  
 Start-End Dates 06/2025-06/2030

**Sponsored research**

Funding Type Sponsored  
 Sponsor Agency and ID # Cleveland Clinic Catalyst Grant  
 Title of Project Functional magnetic resonance imaging of patients receiving intravenous ketamine for treatment resistant bipolar depression

PI of Grant Brian Barnett, MD and Stephen Jones, MD PhD  
 If not PI, Your Role N/A

Percent Effort 0% (no direct salary support; effort covered by department)  
 Total Direct Costs Awarded \$80,000  
 Start-End Dates 06/2023-Present

**Unfunded**

Funding Type Unfunded  
 Sponsor Agency and ID # Cleveland Clinic Center for Populations Health Research statistical collaboration  
 Title of Project Investigating the relationship between LSD use, availability, and associated risk perceptions at the population level  
 PI of Grant Brian Barnett, MD  
 If not PI, Your Role  
 Percent Effort 0% (no direct salary support; effort covered by department)  
 Total Direct Costs Awarded \$0, grant was non-monetary statistical support  
 Start-End Dates 10/2021-Present

**RESEARCH/GRANT SUPPORT (COMPLETED)**

**Federal**

Funding Type Federal  
 Sponsor Agency and ID # PCORI TRD1511-33648  
 Title of Project ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD) (ELEKT-D)  
 PI of Grant Amit Anand, MD  
 If not PI, Your Role Sub-investigator  
 Percent Effort 3%  
 Total Direct Costs Awarded \$11.2 million  
 Start-End Dates 08/2019-05/2023

Funding Type Federal  
 Sponsor Agency and ID # NIH 2P30AI050410-14  
 Title of Project Prevalence of drug resistant TB among outpatients at an HIV-TB clinic in Lilongwe, Malawi  
 PI of Grant Ronald Swanstrom, PhD  
 If not PI, Your Role\*\* Sub-investigator  
 Percent Effort 100%  
 Total Direct Costs Awarded \$2.6 million  
 Start-End Dates 07/2011-07/2012

**Industry**

Funding Type  
 Sponsor Agency and ID # Reunion Neuroscience RE104-201-PPD  
 Title of Project A Multicenter, Randomized, Double-Blind, Parallel-Group Dose-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Patients with Postpartum Depression (PPD)  
 PI of Grant N/A- multisite industry sponsored trial  
 If not PI, Your Role Cleveland Clinic site PI  
 Percent Effort N/A- per participant contract  
 Start-End Dates 03/2024-06/2025

Funding Type Industry  
 Sponsor Agency and ID # MindMed MMED008  
 Title of Project A Phase 2, Multi-center, Randomized, Double-Blind, Parallel- Group, Dose-Finding Study to Assess the Effect of Four Doses of MM-120 (lysergic acid) for the Treatment of Anxiety Symptoms

PI of Grant	N/A- multisite industry sponsored trial
If not PI, Your Role	Cleveland Clinic site PI
Percent Effort	N/A- per participant contract
Start-End Dates	04/2022-04/2024

**Sponsored**

Funding Type	Sponsored
Sponsor Agency and ID #	Cleveland Clinic Catalyst Grant
Title of Project	Identifying our most vulnerable patients before they fall through the cracks: using neighborhood level data to predict risk of repeated psychiatric hospitalizations
PI of Grant	Brian Barnett, MD
If not PI, Your Role	
Percent Effort	0% (no direct salary support; effort covered by department)
Total Direct Costs Awarded	\$35,000
Start-End Dates	09/2022-03/2024

**Unfunded**

Funding Type	Unfunded
Sponsor Agency and ID #	Cleveland Clinic Neurological Institute NICORE statistical support
Title of Project	An analysis of benzodiazepine prescribing by primary care providers in a large healthcare system
PI of Grant	Brian Barnett, MD
If not PI, Your Role	
Percent Effort	0% (no direct salary support; effort covered by department)
Total Direct Costs Awarded	\$0, grant was non-monetary statistical support
Start-End Dates	03/2019-12/2023

**Proposed Research – Pending Review and Awards**

**Private**

Funding Type	Private
Sponsor Agency and ID #	Philanthropic Donor
Title of Project:	Randomized, Double-Blind, Placebo-Controlled Trial of Intravenous Lorazepam Challenge for the Treatment of Catatonia in a Naturalistic Sample
PI of Grant	Brian Barnett, MD
If not PI, Your Role**	
Percent Effort	2%
Total Direct Costs Awarded	\$100,000
Start-End Dates	06/2026-06/2029

Funding Type	Private
Sponsor Agency and ID #	Cleveland Clinic Alcohol Drug and Recovery Center Endowed Chair
Title of Project:	Buprenorphine Induction with Psilocybin for Opioid use Disorder
PI of Grant	Sandeep Nayak, MD
If not PI, Your Role**	Cleveland Clinic site PI
Percent Effort	3%
Total Direct Costs Awarded	\$300,000
Start-End Dates	05/2026-05/2029

**Industry**

Funding Type	Industry
--------------	----------

Sponsor Agency and ID #	Neumarker
Title of Project:	A Naturalistic Study of Open-Label Transcranial Magnetic Stimulation (TMS) and Electroconvulsive Therapy (ECT) for the Treatment of Depression with a Novel, EEG-based, Machine-Learning Classification Biomarker to Assess Response Prediction
PI of Grant	Brian Barnett, MD
If not PI, Your Role**	
Percent Effort	3%
Start-End Dates	05/2026-05/2029

## **BIBLIOGRAPHY**

### **Peer Reviewed Articles**

1. Dixit R, **Barnett B**, Lazarus JE, Tokito M, Goldman YE, Holzbaur EL. Microtubule plus-end tracking by CLIP-170 requires EB1. *Proceedings of the National Academy of Sciences*. 2009 Jan; 106(2): 492-497.
2. Bearnot B, Coria A, **Barnett BS**, Clark EH, Gartland MG, Jaganath D, Mendenhall E, Seu L, Worjolah AG, Carothers CL, Vermund SH, Heimbürger DC. Global Health Research in Narrative: A Qualitative Look at the FICRS-F Experience. *American Journal of Tropical Medicine and Hygiene*. 2014 Nov;91(5):863-868.
3. **Barnett BS**, Gokhale RH, Krysiak R, Kanyemba C, Chikaonda T, Bokosi M, Mukuzunga C, Saidi F, Phiri S, Hoffman IF, Hosseinipour MC. Prevalence of drug resistant TB among outpatients at an HIV/TB clinic in Lilongwe, Malawi. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2015 Dec;109(12): 763-768.
4. **Barnett BS**, Chawez T, Tweya H, Ngambi W, Phiri S and Hosseinipour M. Assessment of non-standard HIV anti-retroviral therapy regimens at Lighthouse Trust in Lilongwe, Malawi. *Malawi Medical Journal*. 2016 Mar;28(1): 6-9.
5. **Barnett B** and Owusu M. Synthetic cannabinoid use in a transitional housing shelter: A survey to characterize awareness of risks and reasons for use. *American Journal of Psychiatry Residents' Journal*. 2016 Oct;11(10): 4-6.
6. Chikaonda T, Nguluwe N, **Barnett B**, Gokhale RH, Krysiak R, Thengolose I, Rosenberg NE, Stanley C, Mpunga J, Hoffman IF, Hosseinipour M, Scott L, and Stevens W. Performance of Xpert® MTB/RIF among tuberculosis outpatients in Lilongwe, Malawi. *African Journal of Laboratory Medicine*. 2017 Mar;6(2): 464.
7. **Barnett BS**, Mulenga M, Kiser MM, and Charles AG. Qualitative analysis of a psychological supportive counseling group for burn survivors and families in Malawi. *Burns*. 2017 May;43(3): 602-607
8. **Barnett BS**, Tarpley MJ, Davidson MA, Gbadero DA. Factors Associated with Perioperative Mortality in Typhoid Fever Patients with Intestinal Perforation in Nigeria. *Integr J Glob Health*. 2017; 1( 2).
9. **Barnett BS**, Kusunzi V, Magola L, Borba CPC, Udedi M, Kulisewa K and Hosseinipour MC. Description of the inpatient population and care received at a psychiatric unit in Lilongwe, Malawi. *International Journal of Culture and Mental Health*. 2018 Mar; 11(4): 574-582.
10. **Barnett BS**, Siu WO, and Pope HG. A survey of American psychiatrists' attitudes towards classical hallucinogens. *Journal of Nervous and Mental Disease*. 2018 Jun;206(6):476-480.
11. **Barnett BS**, Nesbit A, and Sorrentino RM. The transgender bathroom debate at the intersection of politics, law, ethics and science. *Journal of the American Academy of Psychiatry and the Law*. 2018 Jun;46(2): 232-241.
12. **Barnett BS**, Kusunzi V, Magola L, Borba CPC, Udedi M, Kulisewa K and Hosseinipour MC. Factors associated with the use of seclusion in an inpatient psychiatric unit in Malawi. *Malawi Medical Journal*. 2018 Sept; 30(3); 197-204.
13. **Barnett BS**, Kusunzi V, Magola L, Borba CPC, Udedi M, Kulisewa K and Hosseinipour MC. Factors associated with long length of stay in an inpatient psychiatric unit in Lilongwe, Malawi. *Social Psychiatry and Psychiatric Epidemiology*. 2019 Feb;54(2): 235-242.
14. Ward HB, **Barnett BS**, Suzuki J. Rapid transition from methadone to buprenorphine using naltrexone-induced withdrawal: A case report. *Substance Abuse*. 2019 Mar;40(2): 140-145.
15. Twark C, **Barnett B**, Marcovitz D, Kim S, Bogunovic O, Boyajian C, Connery H, and Weiss R. Poster Presentation Abstracts (n=71) Poster 18: Understanding the reasons that patients with opioid use disorder are not initiated on maintenance buprenorphine/naloxone before discharge from a detoxification unit. *American Journal on Addictions*. May 2019; 28(3): 178-179.
16. **Barnett BS** and Bodkin JA. Clinician time expended obtaining prior authorizations for behavioral health admissions. *Psychiatric Services*. 2019 Jun;70(6): 533-534.

17. **Barnett BS**, Kusunzi V, Magola L, Borba CPC, Udedi M, Kulisewa K and Hosseinipour MC. Risk factors for readmission among a cohort of psychiatric inpatients in Lilongwe, Malawi. *International Journal of Psychiatry in Clinical Practice*. 2019 Dec; 4:1-6.
18. **Barnett BS** and Saxton A. Pretrial Detainee's Right to Medical Care. *Journal of the American Academy of Psychiatry and the Law*. 2019 Dec; 47 (4): 508-510.
19. **Barnett BS**. Addressing Sexual Violence in Psychiatric Facilities. *Psychiatric Services*. 2020 May
20. **Barnett BS** and Bodkin JA. More on the travesty of pre-authorization. *Current Psychiatry*. 2020 July
21. **Barnett BS** and Bodkin JA. A survey of US psychiatrists concerning medication prior authorization requirements. *Journal of Nervous and Mental Disease*. 208 (7) 2020 July
22. Carlo A, **Barnett BS**, and Frank RG. Behavioral Health Parity Efforts in the United States. *JAMA*. Published online July 15, 2020. doi:10.1001/jama.2020.3505.
23. **Barnett BS**, Esper F, and Foster C. Keeping the wolf at bay: Infection prevention and control measures for inpatient psychiatric facilities in the time of COVID-19. *General Hospital Psychiatry*. 66 (2020) 51–53. <https://doi.org/10.1016/j.genhosppsych.2020.07.004>.
24. **Barnett BS**. Meditations on involuntary civil commitment amid a pandemic. *Psychiatr Serv*. 2020. appi.ps.71901. doi:10.1176/appi.ps.71901.
25. Carlo AD, **Barnett BS**, Utibe E, and Galea S. Redefining Medicine's Relationship with the Media in the Era of COVID-19. *American Journal of Preventive Medicine*. 2020. doi:<https://doi.org/10.1016/j.amepre.2020.08.016>.
26. Rosenthal RN, Welsh JW, Connery HS, **Barnett BS**, DeVido J, Hill K, Levin FR, Williams AR, Greenfield SF. Advocacy and Public Policy Efforts of the American Academy of Addiction Psychiatry. *Am J Addict*. 2020 Sep;29(5):401-406. doi: 10.1111/ajad.13085. PMID: 32902042.
27. **Barnett BS**, Kudler H, Swanson J. To Prevent Suicide Among Veterans, Their Physicians Should Discuss Gun Safety. *JAMA Health Forum*. Published online November 23, 2020. doi:10.1001/jamahealthforum.2020.1407
28. **Barnett BS** and Doblin R. Dissemination of Erroneous Research Findings and Subsequent Retraction in High-Circulation Newspapers: A Case Study of Alleged MDMA-Induced Dopaminergic Neurotoxicity in Primates J Psychoactive Drugs. 2020 Nov 26:1-7. doi: 10.1080/02791072.2020.1847365. Epub ahead of print. PMID: 33241981.
29. **Barnett BS**, Morris NP. Pharmacy Access to Sterile Injection Supplies for People Who Inject Drugs. *JAMA Intern Med*. Published online November 30, 2020. doi:10.1001/jamainternmed.2020.6840
30. Newlon C, Ayres I, **Barnett B**. Your Liberty or Your Gun? A Survey of Psychiatrist Understanding of Mental Health Prohibitors. *J Law Med Ethics*. 2020 Dec;48(4\_suppl):155-163. doi: 10.1177/1073110520979417. PMID: 33404305.
31. **Barnett BS**. Eastern Kentucky's Lost Generation and the Echoes That Remain—The Aftermath of the Opioid Epidemic. *JAMA Intern Med*. Published online December 14, 2020. doi:10.1001/jamainternmed.2020.7383
32. **Barnett BS**, Morris NP, Suzuki J. Addressing in-hospital illicit substance use. *Lancet Psychiatry*. 2021 Jan;8(1):17-18. doi: 10.1016/S2215-0366(20)30487-9. PMID: 33341161.
33. **Barnett BS**, Carlo AD, Mezzadri A, Ruwanpura KN. The Invisible People Behind Our Masks. *Ann Intern Med*. 2021 Jan 12. doi: 10.7326/M20-7421. Epub ahead of print. PMID: 33428438.
34. **Barnett BS**. Out Of Options For Patients With Serious Mental Illness. *Health Aff (Millwood)*. 2021 Jan;40(1):170-173. doi: 10.1377/hlthaff.2020.00592. PMID: 33400574.
35. Carlo AD, **Barnett BS**, Cella D. Computerized Adaptive Testing (CAT) and the Future of Measurement-Based Mental Health Care. *Adm Policy Ment Health*. 2021 Mar 2:1–3. doi: 10.1007/s10488-021-01123-9.
36. Carlo AD, **Barnett BS**, Unützer J. Harnessing Collaborative Care to Meet Mental Health Demands in the Era of COVID-19. *JAMA Psychiatry*. 2021 Apr 1;78(4):355-356. doi: 10.1001/jamapsychiatry.2020.3216. PMID: 33084852; PMCID: PMC10829844.
37. **Barnett BS**, Wakeman SE, Davis CS, Favaro J, and Rich JD. Expanding Mail-Based Distribution of Drug-Related Harm Reduction Supplies Amid COVID-19 and Beyond. *Am J Public Health*. 2021 Jun;111(6):1013-1017. doi: 10.2105/AJPH.2021.306228. PMID: 33950718; PMCID: PMC8101586.
38. **Barnett BS**, Greer GR. Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer. *J Acad Consult Liaison Psychiatry*. 2021 Jul-Aug;62(4):460-471. doi: 10.1016/j.jaclp.2020.12.011. Epub 2021 Jan 21. PMID: 34210406.
39. Orlins Z, **Barnett B**. Tachycardia during Treatment with Risperidone and Paliperidone Palmitate in a Patient without Previous Cardiovascular Disease. *Case Rep Psychiatry*. 2021 Jul 16;2021:9954991. doi: 10.1155/2021/9954991. PMID: 34336345

40. **Barnett BS**, Carlo AD, Phatak A. Intentional Overdose Prevention in the Era of the 90-Day Prescription. *Psychiatr Serv*. 2021 Aug 9;appips202100050. doi: 10.1176/appi.ps.202100050. Epub ahead of print. PMID: 34369803.
41. **Barnett BS**, Beussant Y, King F 4th, Doblin R. Psychedelic Knowledge and Opinions in Psychiatrists at Two Professional Conferences: An Exploratory Survey. *J Psychoactive Drugs*. 2021 Aug 19;1-9. doi: 10.1080/02791072.2021.1957183. Epub ahead of print. PMID: 34409921.
42. **Barnett BS**, Parker SE, Weleff J. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020. *Int J Drug Policy*. 2021 Oct 5;99:103473. doi: 10.1016/j.drugpo.2021.103473. Epub ahead of print. PMID: 34624734.
43. **Barnett BS**, Carlo AD, Phatak A. In reply: Intentional Overdose Prevention in the Era of the 90-Day Prescription. *Psychiatr Serv*. 2021 Nov 1;72(11):1362. doi: 10.1176/appi.ps.721105. PMID: 34734754.
44. Weleff J, Butler, RS, Stroom D, & **Barnett BS** (2022). Reported firearm access among patients admitted to a dual diagnosis medically-assisted withdrawal unit over five years. *Drug and Alcohol Dependence Reports*, 2, 100034. March 2022. <https://doi.org/https://doi.org/10.1016/j.dadr.2022.100034>
45. Weleff J, Bryant K, Kovacevich A, and **Barnett BS**. Suicide versus Accidental Death by Autoerotic Asphyxiation in a Patient Receiving Intravenous Ketamine for Depression. *Case Reports in Psychiatry*, vol. April 2022. <https://doi.org/10.1155/2022/1104668>
46. Weleff J, **Barnett BS** (shared first authorship), Park DY, Akiki TJ, and Aftab A. The state of the catatonia literature: Employing bibliometric analysis of articles from 1965-2020 to identify current research gaps. *J Acad Consult Liaison Psychiatry*. 2022 Jul 12:S2667-2960(22)00294-4. doi: 10.1016/j.jaclp.2022.07.002. Epub ahead of print. PMID: 35840002.
47. **Barnett BS**, Ziegler K, Doblin R, Carlo AD. Is psychedelic use associated with cancer?: Interrogating a half-century-old claim using contemporary population-level data. *J Psychopharmacol*. 2022 Aug 16:2698811221117536. doi: 10.1177/02698811221117536. Epub ahead of print. PMID: 35971893.
48. **Barnett BS** & Weleff J. Psychedelics in the treatment of substance use disorders. *Psychiatric Annals*. 2022 Sep 52(9) doi: 10.3928/00485713-20220804-01
49. **Barnett BS**. Deepening our understanding of psychedelics by expanding psychedelic data collection in the United States National Survey on Drug Use and Health. *J Psychopharmacol [Internet]*. 2022 Sep 16;02698811221123051. Available from: <https://doi.org/10.1177/02698811221123051>
50. Pan E, Weleff J, Anand A, and **Barnett BS**. Treatment of Misophonia with Risperidone in a Patient with Autism Spectrum Disorder. *Psychiatric Case Reports*. September 2022. <https://doi.org/10.1155/2022/3169834>
51. Weleff J, Akiki TJ, & **Barnett BS**. Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies. *Journal of Psychoactive Drugs*. October 2022. DOI: 10.1080/02791072.2022.2133757
52. Reynolds LM, **Barnett B**, Weleff J, Morunga E, Wells A, Stack A, Akroyd A, Hoeh N, Sundram F, Muthukumaraswamy S, Lawrence N, Evans WJ. The perceptions of cancer health-care practitioners in New Zealand and the USA toward psychedelic-assisted therapy with cancer patients: A cross-sectional survey. *Palliat Support Care*. 2022 Nov 3:1-10. doi: 10.1017/S1478951522001481. Epub ahead of print. PMID: 36325995.
53. **Barnett BS**, Balaji D, Weleff J, Carroll BT. Catatonia and neuroleptic malignant syndrome in patients with cerebral palsy: Two case reports and a systematic review of the literature. *J Acad Consult Liaison Psychiatry*. 2022 Dec 28:S2667-2960(22)00627-9. doi: 10.1016/j.jaclp.2022.12.008. Epub ahead of print. PMID: 36586471.
54. Weleff J, Dore S, Anand A, **Barnett BS**. Black Pepper (*Piper nigrum*) for Tobacco Withdrawal: A Case Report. *Case Rep Psychiatry*. 2022 Dec 9;2022:5908769. doi: 10.1155/2022/5908769. PMID: 36530582; PMCID: PMC9757938.
55. Weleff J, Anand A, Squeri M, Sieke R, Thompson NR, **Barnett BS**. An Analysis of Benzodiazepine Prescribing to Primary Care Patients in a Large Healthcare System from 2019-2020. *J Psychoactive Drugs*. 2023 Mar 20:1-12. doi: 10.1080/02791072.2023.2191610. Epub ahead of print. PMID: 36940298.
56. **Barnett BS**, Ostrovsky A. Psychedelic Medicine's Future Depends on Proactive Development of a Robust Medical Billing and Coding Strategy. *Psychedelic Medicine*. March 2023;1(1):14-17. doi:10.1089/psymed.2022.0005
57. **Barnett BS**, Sweat NW, Hendricks PS. Case report: Prolonged amelioration of mild red-green color vision deficiency following psilocybin mushroom use. *Drug Science, Policy and Law*. May 2023;9. doi:10.1177/20503245231172536
58. Anand A, Mathew SJ, Sanacora G, Murrough JW, Goes FS, Altinay M, Aloysi AS, Asghar-Ali AA, **Barnett BS**, Chang LC, Collins KA, Costi S, Iqbal S, Jha MK, Krishnan K, Malone DA, Nikayin S, Nissen SE, Ostroff

- RB, Reti IM, Wilkinson ST, Wolski K, Hu B. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. *N Engl J Med*. 2023 May 24. doi: 10.1056/NEJMoa2302399. Epub ahead of print. PMID: 37224232.
59. Slavnic B, **Barnett BS**, McIntire S, Becker R, Saba S, Vellanki KD, Honaker L, Weleff J, Carroll BT. Methamphetamine-associated catatonia: Case series and systematic review of the literature from 1943-2020. *Ann Clin Psychiatry*. 2023 Aug;35(3):167-177. doi: 10.12788/acp.0116. PMID: 37459499.
  60. Aday, J. S.\*, **Barnett, B. S.\***, Grossman, D., Murnane, K. S., Nichols, C. D., & Hendricks, P. S. (n.d.). Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry. *Psychedelic Medicine*, 0(0), null. <https://doi.org/10.1089/psymed.2023.0013> \*shared first authorship.
  61. Herrmann, Z., Levin, A. W., Cole, S. P., Slabaugh, S., **Barnett, B.**, Penn, A., Jain, R., Raison, C., Rajanna, B., & Jain, S. (n.d.). Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States. *Psychedelic Medicine*, 0(0), null. <https://doi.org/10.1089/psymed.2023.0030>
  62. Wang PR, Dore S, Weleff J, Butler RS, **Barnett BS**. Phencyclidine Positivity on Urine Drug Screening in Patients Treated for Alcohol Withdrawal on a Dual-diagnosis Medically Assisted Withdrawal Unit. *J Addict Med*. 2023 Aug 23. doi: 10.1097/ADM.0000000000001217. Epub ahead of print. PMID: 37611166.
  63. Young, A., Rucker, J., Eynde, V. V. den, Redhead, C., **Barnett, B.**, Godet, L., Cleare, A., Cosgrove, J., Stahl, S., Birkenhäger, T., & Gillman, P. K. (2023). An Expert Roundtable Discussion on the Use of Classic Monoamine Oxidase Inhibitors in the Treatment of Depression – Part One. *Psychiatric Annals*, 53(8), 359–363. <https://doi.org/10.3928/00485713-20230717-01>
  64. Berk, M., Eynde, V. V. den, Ganapathy, K., Andrade, C., Birkenhäger, T., Bodkin, J. A., Nutt, D., **Barnett, B.**, Feinberg, S. S., Parker, G., Ruhe, E., Fornaro, M., Redhead, C., Godet, L., & Gillman, P. K. (2023). An Expert Roundtable Discussion on the Use of Classic Monoamine Oxidase Inhibitors in the Treatment of Depression – Part Two. *Psychiatric Annals*, 53(8), 364–369. <https://doi.org/10.3928/00485713-20230718-01>
  65. Gillman, P. K., Eynde, V. V. den, Godet, L., Redhead, C., Horwitz, A., & **Barnett, B.** (2023). Monoamine Oxidase Inhibitors and Clinically Relevant Drug Interactions: A Guide for Preventing Serotonin Toxicity and Hypertensive Reactions. *Psychiatric Annals*, 53(8), 353–358. <https://doi.org/10.3928/00485713-20230713-02>
  66. Weleff J, Anand A, Squeri M, Sieke R, Thompson NR, **Barnett BS**. An Analysis of Benzodiazepine Prescribing to Primary Care Patients in a Large Healthcare System from 2019-2020. *J Psychoactive Drugs*. 2023 Mar 20:1-12. doi: 10.1080/02791072.2023.2191610. Epub ahead of print. PMID: 36940298.
  67. Kovacevich A, Weleff J, Claytor B, **Barnett BS**. Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD. *J Psychoactive Drugs*. 2023 Aug 31:1-8. doi: 10.1080/02791072.2023.2253538. Epub ahead of print. PMID: 37650700.
  68. **Barnett BS**, Anand A. Attenuation of severe ketamine-induced neuropsychiatric side effects by lamotrigine in a patient with treatment resistant bipolar depression: A case report. *Psychiatry Research Case Reports*. 2023;2(2):100167. doi:<https://doi.org/10.1016/j.psycr.2023.100167>
  69. Anand A, Weleff J, Thompson NR, and **Barnett BS**. Prescribing of Z-Drugs With and Without Opioid Coprescribing to Primary Care Patients in a Large Health Care System From 2019–2020. *J Clin Psychiatry* 2023;84(6):22m14753
  70. **Barnett BS**, Arakelian M, Beebe D, Ontko J, Riegel C, Siu WO, Weleff J, and Pope HG. American psychiatrists' opinions about classic hallucinogens and their potential therapeutic applications: A seven-year follow-up survey. *Psychedelic medicine*. 2023. Online ahead of print.
  71. Dore S, Weleff J, Anand A, Thompson NR, **Barnett BS**. Race, economic status, and disparities in the receipt of benzodiazepine prescriptions in a large primary care sample. *Gen Hosp Psychiatry*. 2023 Sep 9;85:28-34. doi: 10.1016/j.genhosppsy.2023.09.002. Epub ahead of print. PMID: 37729721.
  72. **Barnett BS**, Bassir Nia A, Sackett NB, Weleff J. Editorial: Psychedelics as treatments for substance use disorders: exploring therapeutic potential, risks, underlying mechanisms of action, and implementation challenges. *Frontiers in Psychiatry*. 2023;14. doi:10.3389/fpsy.2023.1305478
  73. **Barnett BS**, Chai PR, Suzuki J. Scaling Up Point-of-Care Fentanyl Testing - A Step Forward. *N Engl J Med*. 2023 Nov 2;389(18):1643-1645. doi: 10.1056/NEJMp2308525. Epub 2023 Oct 28. PMID: 37902291.
  74. Arakelian M, **Barnett B**, Weleff J. The Zero Suicide Model in Addiction Treatment Settings: Recognizing the Need for Feasibility and Implementation Data. *Psychiatr Serv*. 2023 Nov 7:appips20230175. doi: 10.1176/appi.ps.20230175. Epub ahead of print. PMID: 37933133.
  75. **Barnett BS**, Anand A, Dewey EN, et al. Perceived Risk of Trying Lysergic Acid Diethylamide in the United States from 2015 to 2019: Are Americans Assessing Lysergic Acid Diethylamide's Risk Profile More Favorably? *Psychedelic Medicine*. Published online January 9, 2024. doi:10.1089/psymed.2023.0027

76. Bobak L, Dorney I, Kovacevich A, **Barnett B**, Kaelber DC. Pre-Existing Psychiatric Conditions as Risk Factors for Diagnosed Long COVID-19 Syndrome within Aggregated Electronic Health Record Data. *Psychosom Med*. 2024 Jan 9. doi: 10.1097/PSY.0000000000001280. Epub ahead of print. PMID: 38193771.
77. Weleff, J., Anand, A., Dewey, E. N., & **Barnett, BS**. (2024). LSD use in the United States: Examining user demographics and their evolution from 2015–2019. *Journal of Psychedelic Studies* (published online ahead of print 2024). <https://doi.org/10.1556/2054.2024.00309>
78. **Barnett BS**. Formulary Coverage of Esketamine and Ketamine for Depression in Ohio Health Insurance Marketplace and Medicaid Plans. *J Psychiatr Pract*. 2024 Mar 1;30(2):130-133. doi: 10.1097/PRA.0000000000000766. PMID: 38526400.
79. Aghaei AM, Weleff J, Martins B, Ing K, Fontenele R, **Barnett BS**, Anand A, Bassir Nia A. Psychotherapeutic Interventions in Clinical Trials of Psychedelics for the Treatment of Alcohol Use Disorder. *Curr Addict Rep* **11**, 685–712 (2024). <https://doi.org/10.1007/s40429-024-00574-y>
80. Ostrovsky A, **Barnett B**. New Billing Codes Offer Opportunity to Investigate Psychedelic Treatment. *Psychedelic Medicine*. Published online May 2024. doi:10.1089/psymed.2023.0071
81. Jha MK, Wilkinson ST, Krishnan K, Collins KA, Sanacora G, Murrrough J, Goes F, Altinay M, Aloysi A, Asghar-Ali A, **Barnett B**, Chang L, Costi S, Malone D, Nikayin S, Nissen SE, Ostroff R, Reti I, Wolski K, Wang D, Hu B, Mathew SJ, Anand A. Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Netw Open*. 2024 Jun 3;7(6):e2417786. doi: 10.1001/jamanetworkopen.2024.17786. PMID: 38916891.
82. **Barnett BS**, Koons CJ, Van den Eynde V, Gillman PK, Bodkin JA. Hypertensive Emergency Secondary to Combining Psilocybin Mushrooms, Extended Release Dextroamphetamine-Amphetamine, and Tranylcypromine. *J Psychoactive Drugs*. 2024 Jun 21:1-7. doi: 10.1080/02791072.2024.2368617. Epub ahead of print. PMID: 38903003.
83. Kleinman RA, **Barnett BS**. Smoking Cessation as a Priority for Psychiatrists. *JAMA Psychiatry*. 2024 Jul 31. doi: 10.1001/jamapsychiatry.2024.2162. Epub ahead of print. PMID: 39083329.
84. **Barnett BS**, Vest MF, Delatte MS, King Iv F, Mauney EE, Coulson AJ, Nayak SM, Hendricks PS, Greer GR, Murnane KS. Practical considerations in the establishment of psychedelic research programs. *Psychopharmacology (Berl)*. 2024 Dec 4. doi: 10.1007/s00213-024-06722-6. Epub ahead of print. PMID: 39627438.
85. Kleinman RA, **Barnett BS**. Eliminating the Medicare Coverage Gap for Intranasal Naloxone and Nicotine Replacement Therapy. *JAMA*. 2025 Feb 5. doi: 10.1001/jama.2024.28394. Epub ahead of print. PMID: 39908047.
86. **Barnett BS**. Funding Success of United States Federal Grant Applications Proposing to Study Therapeutic Applications of Psychedelics: A Survey Study. *Psychoactives*. 2025; 4(1):4. <https://doi.org/10.3390/psychoactives4010004>
87. **Barnett BS**, Weiss RD, Sanacora G. Strengthening Safeguards for Psychiatric Uses of Ketamine. *JAMA Psychiatry*. 2025 Feb 12. doi: 10.1001/jamapsychiatry.2024.4787. Epub ahead of print. PMID: 39937465.
88. Katkar R, Perez AM, Altinay M, **Barnett BS**. Exploring Gender-Themed Lysergic Acid Diethylamide Experiences: A Subreddit Analysis. *Psychedelic Medicine*. 0(0):null. doi:10.1089/psymed.2024.0025 2025 Feb.
89. Sanacora G, **Barnett BS**, Hu B, et al. Patient preference effects in a randomized comparative effectiveness study of electroconvulsive therapy and ketamine for treatment resistant depression: An ELEKT-D trial secondary analysis. *Psychiatry Research*. Published online 2025:116411. doi:<https://doi.org/10.1016/j.psychres.2025.116411>
90. Bobak L, Dorney I, Kovacevich A, **Barnett BS**. Therapeutic Potential of Psilocybin for Treating Neuropsychiatric Long COVID Symptoms: A Reddit Investigation. *J Psychoactive Drugs*. 2025 Mar 14:1-9. doi: 10.1080/02791072.2025.2478097. Epub ahead of print. PMID: 40084630.
91. Weleff J, Pulido-Saavedra A, Aghaei AM, Ing K, Arakelian M, Fontenele R, Nero N, **Barnett BS**, Anand A, Bassir Nia A, Angarita GA. The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies. *Psychiatry Res*. 2025 Mar 15;348:116446. doi: 10.1016/j.psychres.2025.116446. Epub ahead of print. PMID: 40147088.
92. Kovacevich A, Dorney I, Bobak L, Kaelber DC, **Barnett BS**. Therapeutic Potential of Psychedelics for Treating Anosmia: An Investigation of Online Accounts. *J Psychoactive Drugs*. 2025 Mar 1:1-6. doi: 10.1080/02791072.2025.2474239. Epub ahead of print. PMID: 40022524.
93. **Barnett BS**, Mauney EE, King F 4th. Psychedelic-assisted therapy: An overview for the internist. *Cleve Clin J Med*. 2025 Mar 3;92(3):171-180. doi: 10.3949/ccjm.92a.24032. PMID: 40032306.

94. Yermal J, Costa G P, Weleff J, Koomson W, **Barnett BS**, & Anand A. (April 14, 2025) Characteristics and Trends of NIH-Funded Opioid Use Disorder Clinical Trials During the Opioid Epidemic With a Focus on Gender. *Cureus* 17(4): e82227. doi:10.7759/cureus.82227
95. Dhaliwal OM, Bobak L, **Barnett BS**. Ensuring Access to Psychedelic-Assisted Therapy in Rural Communities. *Psychedelic Med (New Rochelle)*. 2025 May 26;3(2):66-70. doi: 10.1089/psymed.2024.0018. PMID: 40530403; PMCID: PMC12169206.
96. **Barnett BS** & Francis A. Fluctuation of Catatonic Signs in a Naturalistic Clinical Sample. *Annals of Clinical Psychiatry*. 2025 Jun 25;0(0). doi:10.1177/10401237251344102. Epub ahead of print.
97. Rached G, Fiani D, Campana AM, Ferber S, **Barnett BS**. Rapid Monoamine Oxidase Inhibitor Switches in Treatment-Resistant Depression: Safety Evaluation in 3 Cases. *J Psychiatr Pract*. 2025 Jul 1;31(4):222-226. doi: 10.1097/PRA.0000000000000869. PMID: 40679804.
98. **Barnett BS**, Anand A, Dewey EN, Hoffer L, and Weleff J. Perceived availability of lysergic acid diethylamide (LSD) in the United States from 2015-2019. *Psychedelic Medicine*. 2025 Jul 2. <https://doi.org/10.1089/psymed.2024.0045>. Epub ahead of print.
99. **Barnett BS**, Arakelian M, Weleff J, Squier-Roper T, King F 4th, Cumming D, Falcone T. Psychiatric Residents' Perspectives on Psychedelics and Psychedelic Assisted Therapy. *J Psychoactive Drugs*. 2025 Jul 2:1-11. doi: 10.1080/02791072.2025.2527296. Epub ahead of print. PMID: 40600242.
100. **Barnett BS**, Anand A, Weleff J, King F 4<sup>th</sup>, and Dewey EN. Who keeps using LSD?: Correlates of past-year LSD use in people who initiated LSD use at least five years ago. *Psychedelic Medicine*. 2025 Aug 13. <https://doi.org/10.1177/28314425251367321>. Epub ahead of print.
101. Kumpf KT, Wilkinson ST, Hu B, Chen R, Krishnan K, Chakrabarti S, Rhee TG, Grezmak T, Mathew SJ, Sanacora G, Murrough JW, Goes FS, Collins KA, **Barnett BS**, Anand A. Comparing the Cognitive Effects of Repeated Intravenous Ketamine and Electroconvulsive Therapy in Patients With Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D Trial. *J Clin Psychiatry*. 2025 Sep 3;86(4):25m15781. doi: 10.4088/JCP.25m15781. PMID: 40900112.
102. **Barnett BS**, Anand A, Falcone T, Altinay M, Dewey EN, Weleff J. Past-Year Lysergic Acid Diethylamide Use in United States Sexual Minorities from 2015 to 2019. *Psychedelic Med*. Epub ahead of print. 2025 Dec 26. doi:10.1177/28314425251410086
103. **Barnett BS**. Esketamine implementation challenges in psychiatry: A qualitative analysis of mental healthcare providers' social media commentary. *Annals of Clinical Psychiatry*. **In press**.
104. Rached G, Campana A, Fiani D, Nguyen C, Van den Eynde V, Gillman PK, **Barnett BS**. Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances: A Narrative Review of Potential Drug Interactions and Substance Use Disorder Treatment Efficacy Data. *CNS Drugs*. **In press**.
105. Karthan J, Tristano A, **Barnett BS**, and Burns N. Successful treatment of risperidone-induced neuroleptic malignant syndrome followed by safe initiation of aripiprazole lauroxil: A case report. **Under review**.
106. **Barnett BS** & Yockey A. Divergent correlates of lifetime nitrous oxide, phencyclidine, and ketamine use among United States adults. **Under review**.
107. Tosta GF, Salzman B, Harp J, Basra A, **Barnett BS**, Anand A. Adjunctive Oral Naltrexone for Breakthrough Craving in Patients Receiving Extended-Release Injectable Naltrexone for Alcohol Use Disorder: A Case Series. **Under review**.
108. Anand A, Kilbane K, Delos Reyes C, Lackamp J, Gupta N, Pozuelo L, Ronis RJ, **Barnett BS**. A Citywide Collaboration to Expand Addiction Psychiatry Training: Development of a Multi-Institution Fellowship Model. **Under review**.
109. King F IV, **Barnett BS**, Taylor T, Mattson SA, Zambrano J, Forcen FE, Nigam K, Mauney E, Stern TA. Medical Sequelae of Psychedelic Use. **Under review**.
110. King F IV, Zambrano J, Mauney E, Nigam K, Forcen FE, **Barnett BS**, Taylor T, Mattson SA, Stern TA. Psychological Adverse Effects of Psychedelic Use. **Under review**.

#### **Invited, Peer Reviewed**

1. **Barnett BS** & Greer GR. Psychedelic psychiatry and the C-L psychiatrist: A primer, *Journal of the Academy of Consultation-Liaison Psychiatry* (2021), doi: <https://doi.org/10.1016/j.jaclp.2020.12.011>.

#### **Invited, Non-Peer Reviewed**

1. Christie C, Baker C, Cooper R, Kennedy PJ, Madras B, and Bondi P. The President's Commission on Combating Drug Addiction and the Opioid Crisis. Commission Report. November 2017. Reference #215 discusses my contribution of a section on insurance issues.
2. Rosenthal RN, Welsh JW, Connery HS, **Barnett BS**, DeVido J, Hill K, Levin FR, Williams AR, Greenfield SF. Advocacy and Public Policy Efforts of the American Academy of Addiction Psychiatry. *Am J Addict*. 2020 Sep;29(5):401-406. doi: 10.1111/ajad.13085. PMID: 32902042.

### **Book & Book Chapters**

1. **Barnett BS**, Chu Y, Eshel N, Giovane RA, Hill C, Kapulsky L, Okkels N, Pinar Tonguc, Rose AB, Shah MJ, and Silverberg B. Notes in Psychiatry: Study Notes for Medical Students (ebook). Acute Psychiatry. First edition. Risskov, Denmark, Medical E-books, 2016, 8-23.
2. **Barnett BS** & Suzuki J: Hallucinogen-related disorders. In: Sadock BJ, Sadock VA, Ruiz P, eds. Kaplan & Sadock's Comprehensive Textbook of Psychiatry. 11th ed. Philadelphia, PA. Wolters Kluwer. 2024.
3. Salzman B & **Barnett BS**. Lysergic Acid Diethylamide (LSD) for Alcoholism: Meta-Analysis of Randomized Controlled Trials. In: Weleff J, ed. 50 Studies Every Addiction Doctor Should Know. 1<sup>st</sup> ed. Oxford, United Kingdom. Oxford University Press. **In press**.
4. **Barnett BS**. Monoamine Oxidase Inhibitors (MAOIs). Pocket Psychiatry. 2<sup>nd</sup> ed. Philadelphia PA. Lippincott Williams & Wilkins. **In press**.

### **Media writings**

1. **Barnett B**, Resolve in the face of overwhelming challenges: My glimpse into Nigerian medicine, *AMSA's Global Pulse*, 2010 April; 6(1).
3. **Barnett B** Impairment/Empowerment. *Tabula Rasa*. 2010 May; volume 4.
4. **Barnett B** and Nia AB. Synthetic cannabinoids and the pressing need to detect the undetectable. *American Academy of Addiction Psychiatry News*. Fall 2016; 32(3): 12, 16.
5. **Barnett B** and Connery HS. Implementation challenges of the final rule of Title 42 of the Code of Federal Regulations part 2: Can privacy endure in an era of electronic health information exchange? *American Academy of Addiction Psychiatry News*. Spring 2017; 33(1): 8,19.
6. **Barnett B**. Recent Judicial Gains for Substance Use Disorder Anti-discrimination Efforts. *American Academy of Addiction Psychiatry News*. Summer 2017; 33(2): 8,15.
7. **Barnett B**. Insurers are making it harder for me to treat my opioid-addicted patients. *Washington Post*. April 24, 2018.
8. **Barnett B**. Insurance Companies Set An Unreasonable Bar For Mental Health Coverage. *Huffpost*. May 9, 2018.
9. **Barnett B**. Psychedelics Are Promising, But Many Psychiatrists Don't Want to Use Them. *Vice*. June 19, 2018.
10. **Barnett B**. America Can't Incarcerate Away Our Mental Health Crisis. June 22, 2018. *Huffpost*.
11. **Barnett B**. Jails and prisons: the unmanned front in the battle against the opioid epidemic. July 2, 2018. *STAT*.
12. **Barnett B**. America's Return to the Cave and Precious Moment of Unity. *Lexington Herald Leader*. July 13, 2018.
13. **Barnett B**. Prior Authorizations for Medication Assisted Treatment: Injustice Disguised as Nuisance. *American Academy of Addiction Psychiatry News*. Summer 2018; 34(2).
14. **Barnett B**. Anti-Trans 'Bathroom Bills' Are Based On Lies. Here's The Research To Show It. September 11, 2018. *Huffpost*.
15. **Barnett B**. An addiction specialist explains the benefit in Issue 1. *Akron Beacon Journal*. November 4, 2018.
16. **Barnett B**. Pregnant and Scared to Get Treatment: When Conception Meets Addiction. *The Fix*. February 27, 2019.
17. **Barnett B**. Bridging the Addiction Treatment Community and the Judicial System Through Forensic Psychiatry. *Newsletter of the American Academy of Psychiatry and the Law*. Vol 44, No 1. January 2019.
18. **Barnett B**. National support for 'red-flag' gun laws could prevent many suicides. *STAT*. September 20, 2019.
19. **Barnett B**. Red-Flag Laws Could Stop Suicides. *Wall Street Journal*. September 23, 2019.
20. **Barnett B**. An addiction shouldn't cost you a college degree. *The Hill*. November 5, 2019.
21. **Barnett B**. Waking up to the sexual violence in America's psychiatric units. *KevinMD.com*. December 24, 2019.
22. **Barnett B**. The 90-Day Prescription Isn't for Everyone. *Wall Street Journal*. February 6, 2020.

23. **Barnett B.** Envisioning the End of Financial Aid Disqualification After Drug-Related Convictions. American Academy of Addiction Psychiatry News. Spring 2020; 36(1).
24. **Barnett B.** How policymakers can help smokers quit now. The Hill. April 12, 2020.
25. **Barnett B.** On opioid addiction treatment, Ohio can learn from Massachusetts. Columbus Dispatch. April 13, 2020.
26. **Barnett B** and Turban J. COVID-19 is ravaging America's psychiatric facilities. The Hill. April 27, 2020.
27. **Barnett B.** How the pandemic complicates psychiatry: COVID-19 makes involuntary confinement even more difficult. New York Daily News. May 3, 2020.
28. **Barnett B** and Turban J. Capitalizing on Smoking Cessation Could Curb Coronavirus Deaths. The Fix. May 13, 2020.
29. **Barnett B,** Carlo A and Schwartz B. America's mental health is under siege — Congress can help now. The Hill. June 11, 2020.
30. **Barnett B** and Anand A. The High Price of Ignoring Disease in the Marginalized. Doximity OpMed. July 31, 2020.
31. **Barnett B.** Are we paying COVID-19 vaccine trial participants enough? September 25, 2020.
32. **Barnett B** and Anand A. Climate Anxiety and Mental Illness. Scientific American. October 10, 2020.
33. **Barnett B.** Who's choosing Americans' medications — doctors or insurers? The bane of prior authorization. STAT. January 1, 2021.
34. **Barnett B** and Weleff J. Biden Fumbles Early on Opioid Addiction. Wall Street Journal. February 8, 2021.
35. Marcovitz D and **Barnett B.** The Case for Moving Forward on Eliminating X-Waiver. Psychiatric News. June 1, 2021. <https://doi.org/10.1176/appi.pn.2021.6.28>.  
<https://psychnews.psychiatryonline.org/doi/10.1176/appi.pn.2021.6.28>
36. **Barnett B,** Doblin R, and Holland J. NIH: It's time to make your mark on the renaissance of medicinal psychedelics. STAT. June 2, 2021. <https://www.statnews.com/2021/06/02/nih-make-mark-renaissance-psychedelic-medicine/>
37. Wakeman S, Davis C, and **Barnett B.** Let Former Opioid Users Keep On Trucking. Wall Street Journal. October 31, 2022. <https://www.wsj.com/articles/opioid-users-trucking-drug-policy-regulations-supply-chain-methadone-buprenorphine-drug-addiction-11635708444>
38. **Barnett B.** Flawed FDA safety requirements are hamstringing a highly effective treatment for severe schizophrenia. STAT. May 5, 2022. <https://www.statnews.com/2022/05/05/flawed-fda-safety-requirements-hamstring-highly-effective-schizophrenia-treatment/>.
39. **Barnett BS & Pozuelo L.** Preparing for psychedelic medicine's return. Becker's Behavioral Health. January 18, 2024. <https://www.beckersbehavioralhealth.com/behavioral-health-mental-health/preparing-for-psychedelic-medicines-return.html>

### **Media Appearances & Coverage / Podcasts**

1. Lindsay Kalter. Father, son share addiction recovery on Father's Day. Boston Herald. June 17, 2018. Newspaper interview.
2. Michelangelo Signorile. Interview regarding research on transgender rights and bathroom access. Michelangelo Signorile Show. September 12, 2018. Radio interview.
3. Nelson R. The Opioid Crisis: Treatment Efforts Exclude Inmates. Vol 119, No 8. August 2019. American Journal of Nursing. Journal interview.
4. Emily Hamilton. Red Flag Law Could Stop Suicides. News 5 Cleveland. September 26, 2019. Television interview.
5. Maggie O'Neill. Is Vaping Addictive? Here's What You Need to Know. Health.com. October 23, 2019. Website interview.
6. Erica Foreman. Evidence Lacking to Show Marijuana Products Benefit Mental Health. Cleveland Clinic News Service. November 6, 2019. Television interview.

7. Becky Upham. Smoking Increases Risk for Depression and Schizophrenia, Study Suggests. Everyday Health. November 6, 2019. Website interview.
8. Maggie O'Neill. What Are Brain Zaps? A Psychiatrist Explains the Antidepressant Withdrawal Symptom. Health.com, December 30, 2019. Website interview.
9. Korin Miller. Jessica Simpson's Husband Gave up Alcohol When She Did—Here's Why Experts Say Supporting a Sober Partner Is "Crucial". January 28, 2020. Magazine interview.
10. Meghan Rabbitt. What is Serotonin and How Does it Affect Your Mood? Health Magazine. March 4, 2020. Magazine interview.
11. Katie O'Connor. Can Psychedelics Radically Change SUD Treatment? Psychiatric News. March 2020. Newsletter interview.
12. Cleveland Clinic Health Essentials., How to Overcome Mask Anxiety, 02/09/2020. Website interview.
13. Able Channel. Surviving Suicide. Television interview. November 22, 2020.
14. Cleveland Clinic Health Essentials. A Comprehensive Guide to Face Masks. December 4, 2020. Website interview.
15. NBC WKYC Channel 3: 3 things to know with Stephanie Haney podcast. Why are moms microdosing mushrooms? A Cleveland Clinic doctor explains. July 12, 2022. TV interview. <https://www.wkyc.com/video/syndication/podcasts/3-things-to-know/why-are-moms-microdosing-mushrooms-a-cleveland-clinic-doctors-explains/95-bb69cce8-dc04-415b-8d82-1a596fa1efe8>
16. Psypost: Large national survey suggests that the use of psychedelics is not associated with lifetime cancer development. October 18, 2022. Website interview. <https://www.psypost.org/large-national-survey-suggests-that-the-use-of-psychedelics-is-not-associated-with-lifetime-cancer-development/>
17. NBC WKYC Channel 3 Cleveland. 'Breakthrough therapy'? The strange trip of psychedelic research lands in Ohio. February 16, 2023. <https://www.wkyc.com/article/news/health/breakthrough-therapy-psychedelic-research-ohio/95-537ecb29-3c1c-4f83-af05-f65a06c7561a>
18. Ideastream Public Media WOSU. Can LSD help treat anxiety? Researchers at the Cleveland Clinic want to find out. March 6, 2023. Radio interview. <https://www.wosu.org/2023-03-02/can-ldd-help-treat-anxiety-researchers-at-the-cleveland-clinic-want-to-find-out>
19. Neuro Pathways. Psychedelics: A Reemerging Treatment for Behavioral Health Conditions. April 1, 2023. Podcast interview. <https://my.clevelandclinic.org/podcasts/neuro-pathways/psychedelics-a-reemerging-treatment-for-behavioral-health-conditions>
20. Cleveland.com. LSD to treat severe anxiety? Cleveland Clinic at forefront of psychedelic research. April 15, 2023. News article interview. <https://www.cleveland.com/metro/2023/04/lsd-to-treat-severe-anxiety-cleveland-clinic-at-forefront-of-psychedelic-research.html>
21. Gizmodo. Doing Shrooms Might Have Improved a Man's Color Blindness, Doctors Say. May 5, 2023. Website interview. <https://gizmodo.com/psilocybin-magic-mushrooms-color-blindness-red-green-1850406038>
22. Gilbert D, Executive behind ChatGPT pushes for a new revolution: Psychedelics. 22/04/2023, newspaper interview (Washington Post).
23. Fox8 Cleveland. Should psychedelics be used for therapy? Psychiatrists think so. September 22, 2023. TV interview. <https://fox8.com/news/should-psychedelics-be-used-for-therapy-psychiatrists-think-so/>
24. Crain's Cleveland Business. Ketamine clinics hope to 'open new doors' for patients with severe depression. October 12, 2023. <https://www.crainscleveland.com/health-care/ohio-clinics-offer-ketamine-treatment-depression>
25. Cleveland Clinic ConsultQD. 75 Years Later: Cleveland Clinic Recalls Researchers' Pivotal Role in Discovery of Serotonin. October 27, 2023. <https://consultqd.clevelandclinic.org/75-years-later-cleveland-clinic-recalls-researchers-pivotal-role-in-discovery-of-serotonin>
26. Toledo Blade. Heightened senses: Colors of music underscore unusual condition in synesthesia . October 15, 2023. Newspaper interview. <https://www.toledoblade.com/health-well-being/2023/10/15/colors-of-music-underscores-unusual-condition/stories/20231011104>

27. NBC WKYC Channel 3 Cleveland. Cleveland Clinic addiction specialist writes about the need for accurate fentanyl testing in overdoses. October 28, 2023. TV interview. <https://www.wkyc.com/article/news/health/the-need-for-accurate-fentanyl-testing-in-overdoses-cleveland-clinic/95-2dc2e800-848d-4458-92ce-0d2754f5688a>
28. ABC News 5 Cleveland. Could psychedelics be approved for medical treatment in the near future? December 6, 2023. TV interview. <https://www.news5cleveland.com/news/local-news/could-psychedelics-be-approved-for-medical-treatment-in-the-near-future>
29. NBC WKYC Channel 3 Cleveland. Psychedelic research: Company files for FDA approval of MDMA to help treat PTSD. December 14, 2023. TV interview. <https://www.wkyc.com/article/news/health/psychedelic-research-fda-mdma-ptsd/95-770ca0d7-093e-44fa-8d57-226213744ed1>
30. STAT. Biden changes will force health insurers to speed up and get more specific if they want to deny care. January 17, 2024. Website interview. <https://www.statnews.com/2024/01/17/prior-authorization-health-insurance-white-house/>
31. NBC WKYC Channel 3 Cleveland. Cleveland Clinic begins psilocybin study for depression. March 5, 2024. TV interview. <https://www.wkyc.com/article/news/health/mental-health/cleveland-clinic-begins-psilocybin-study-depression/95-1d41818e-58fc-4e77-a464-f679e69a269b>
32. Fox 8 Cleveland. Cleveland Clinic to test ‘magic mushrooms’ as treatment for this. March 9, 2024. TV interview. <https://fox8.com/news/cleveland-clinic-to-test-psilocybin-as-depression-treatment/>
33. ABC News 5 Cleveland. Cleveland Clinic researches magic mushrooms as potential mental health treatment. March 11, 2024. TV interview. <https://www.news5cleveland.com/news/local-news/cleveland-clinic-researches-magic-mushrooms-as-potential-mental-health-treatment>
34. Spectrum News. LSD trial helps woman with generalized anxiety disorder. March 12, 2024. TV interview. <https://spectrumnews1.com/oh/columbus/news/2024/03/07/lsd-trial-generalized-anxiety-disorder>
35. Cleveland Clinic Newsroom. Why Researchers are Studying Use of Psychedelics. Press release. March 22, 2024. <https://newsroom.clevelandclinic.org/2024/03/22/why-researchers-are-studying-use-of-psychedelics>
36. ABC Channel 33 WYTV Youngstown. Doctors studying use of psychedelics for mental health treatment. March 24, 2024. TV interview. <https://www.wytv.com/news/local-news/doctors-studying-use-of-psychedelics-for-mental-health-treatment/>
37. HCPLive. Psychedelics Fitting into the SUDs Treatment Paradigm. May 9, 2024. Website interview. <https://www.hcplive.com/view/brian-barnett-md-psychedelics-fitting-into-the-suds-treatment-paradigm>
38. Cleveland.com. Woman free of anxiety meds 1 year after Cleveland Clinic LSD trial success. May 15, 2024. Newspaper interview. <https://www.cleveland.com/medical/2024/05/woman-free-of-anxiety-meds-1-year-after-cleveland-clinic-lsd-trial-success.html>
39. Cleveland Clinic ConsultQD. Specialized Clinic Broadens Scope to Manage Patients with Treatment-Resistant Psychiatric Illness. April 12, 2024. <https://consultqd.clevelandclinic.org/specialized-clinic-broadens-scope-to-manage-patients-with-treatment-resistant-psychiatric-illness>
40. Colorado Public Radio. Western medicine is embracing psychedelic research. Colorado is home to one of the world’s largest psilocybin trials. Radio interview. June 4, 2024. <https://www.cpr.org/2024/06/04/psilocybin-cancer-trial-inside-colorado-psychedelic-mushroom-study/>
41. ABC News. FDA rejects MDMA in combination with therapy as treatment for PTSD. Interview for online news article. August 9, 2024.
42. NBC News.. FDA rejects MDMA-assisted therapy for PTSD. Interview for online news article. August 9, 2024.
43. CNN. FDA rejection of MDMA-assisted therapy rattles advocates but doesn’t spell end of psychedelics in medicine, experts say. Interview for online news article. August 13, 2024.
44. Spectrum News. Psilocybin for depression. Video interview. September 4, 2024. [mms.tveyes.com/MediaCenterPlayer.aspx?u=aHR0cDovL211ZGllhY2VudGVyLnR2ZXllcy5jb20vZG93bmxvYWRnYXRld2F5LmFzcHg%2FVXNlcklEPTExMzcwODQmTURJRD0yMjEzMDk0MyZNRFRlZlZlZWQ9NjM4JlR5cGU9TWVkaWE%3D&expand=true](https://mms.tveyes.com/MediaCenterPlayer.aspx?u=aHR0cDovL211ZGllhY2VudGVyLnR2ZXllcy5jb20vZG93bmxvYWRnYXRld2F5LmFzcHg%2FVXNlcklEPTExMzcwODQmTURJRD0yMjEzMDk0MyZNRFRlZlZlZWQ9NjM4JlR5cGU9TWVkaWE%3D&expand=true)

45. Cleveland Clinic ConsultQD. Novel, Fast-Acting Psychedelic May Provide New Avenue for the Treatment of Postpartum Depression. February 6, 2025. <https://consultqd.clevelandclinic.org/novel-fast-acting-psychedelic-may-provide-new-avenue-for-the-treatment-of-postpartum-depression>
46. WKYC Channel 3, local NBC affiliate. Prescription for Life. February 26, 2025. [Prescription for Life | wkyc.com](https://www.wkyc.com/prescription-for-life/)
47. Becker's Behavioral Health. Cleveland Clinic is digging deeper on ketamine. March 5, 2025. <https://www.beckersbehavioralhealth.com/behavioral-health-mental-health/cleveland-clinic-is-digging-deeper-on-ketamine/>
48. WKYC Channel 3, local NBC affiliate. Cleveland Clinic explores novel psychedelic drug for use against postpartum depression. March 14, 2025. <https://www.wkyc.com/article/news/health/cleveland-clinic-study-single-dose-psychedelic-postpartum-depression/95-118ecef3-5644-4b8e-bba9-b3d482d77eb3>
49. Ivanhoe News. Psychedelics Solution: A Dose of Hope. April 16, 2025. <https://www.ivanhoe.com/family-health/psychedelics-solution-a-dose-of-hope/>
50. Cleveland.com. Cleveland Clinic investigates synthetic psychedelic drug for postpartum depression. April 25, 2025. [Cleveland Clinic investigates synthetic psychedelic drug for postpartum depression - cleveland.com](https://www.cleveland.com/health/2025/04/25/cleveland-clinic-investigates-synthetic-psychedelic-drug-for-postpartum-depression/)
51. Cleveland Clinic ConsultQD. Risks and Rewards of Low-Dose Ketamine for Managing Treatment-Resistant Depression. April 30, 2025. <https://consultqd.clevelandclinic.org/risks-and-rewards-of-low-dose-ketamine-for-managing-treatment-resistant-depression>
52. Cleveland Clinic Newsroom. How Psychedelics Could Help Treat Anxiety and Depression. May 5, 2025. <https://newsroom.clevelandclinic.org/2025/05/05/how-psychedelics-could-help-treat-anxiety-and-depression>
53. Fox Channel 8 Cleveland. Morning show live interview on psychedelics for anxiety. May 14, 2025.
54. FirstWord Pharma. Gilgamesh's next-gen psychedelic could challenge Spravato in MDD. June 25, 2025. <https://firstwordpharma.com/story/5976198>
55. West Palm Beach Channel 12 CBS News. Psychedelic research offers hope for those resistant to mental health treatments. June 11, 2025. <https://cbs12.com/news/local/psychedelic-research-offers-hope-for-those-resistant-to-mental-health-treatments>
56. Nashville Banner. One Nashville Family's Struggle with Autism — and the Breakthrough That Politics Could Stop Cold. July 1, 2025. <https://nashvillebanner.com/2025/07/01/autism-catatonia-treatment-study/>

### **Abstract Presentations**

1. **Barnett B**, Ball L, Magola L and Hosseinipour M. Characteristics of the inpatient population and care received at the Bwaila District Hospital psychiatric unit in Lilongwe, Malawi. European Psychiatry, 2013, volume 28, Supplement 1, Page 1, European Psychiatric Association Congress, Nice, France, 04/2013.
2. Dooner A, Shin SDK, **Barnett B**, Anand A, & Jenks B. Naltrexone-Precipitated Withdrawal in a Patient with an Intrathecal Opioid Pump. Ohio Society of Addiction Medicine Annual meeting. October 2022. Columbus, Ohio.